DolceraWiki - User contributions [en]

Olympus Corporation- Company Profile

2011-09-19T16:22:32Z

Abhay.goel: /* Projections for FY 2012 */

==Company overview==

OLYMPUS CORPORATION, a Japan-based manufacturer, mainly manufactures and sells medical products, life and industrial products, imaging products, information communication products and other products. The Company operates in five business segments.
* The Medical segment is engaged in the manufacture and sale of medical endoscopes, surgical endoscopes, endoscope disposal equipment and ultrasonic endoscopes.
* The Life and Industrial segment provides biological microscopes, industrial microscopes, endoscopes for industrial use and non-destructive testing equipment.
* The Imaging segment is engaged in the manufacture and sale of digital cameras and voice recorders.
* The Information Communication segment is engaged in the sale of mobile terminals, such as cellular phones.
* The Others segment is engaged in the development of biomaterials and systems, industrial endoscopes, nondestructive inspection equipment, printers, mobile solutions and mobile contents services, the development and sale of package software, the sale of semiconductor-related equipment and electronic machines, as well as the development of systems.

 
In August 2009, the Company disposed its analytical equipment business to its wholly owned subsidiary, which has been engaged in the manufacturing and sale of clinical laboratory examination equipment. In addition, the Company has sold the subsidiary to Beckman Coulter, Inc. on August 1, 2009. As a result, the Company holds no stake in the subsidiary. 
As of March 31, 2011, the Company has 188 subsidiaries and 11 associated companies.

{|border="2" cellspacing="0" cellpadding="4" width="54%" align="center"
|bgcolor = "#DBE5F1"|'''Type'''
|Public Company
|-
|bgcolor = "#DBE5F1"|'''Company Size'''
|34,391 employees
|-
|bgcolor = "#DBE5F1"|'''Website'''
|[http://www.olympus-global.com/en/ www.olympus-global.com]
|-
|bgcolor = "#DBE5F1"|'''Founded'''
|1919
|-
|bgcolor = "#DBE5F1"|'''Headquarters'''
|Tokyo, Japan
|-
|bgcolor = "#DBE5F1"|'''Regional involvement'''
|Worldwide
|-
|bgcolor = "#DBE5F1"|'''Employees'''
|34,391
|-
|bgcolor = "#DBE5F1"|'''Chairman & CEO'''
|Tsuyoshi Kikukawa
|-
| bgcolor = "#DBE5F1"|'''President & COO'''
|Michael C. Woodford
|-
|}
 
The company operates under the following business lines:

[[Image:Business_lines.PNG|centre]]

==Financial overview==
{|border="2" cellspacing="0" cellpadding="4" width="71%" align="center"
|bgcolor = "#4F81BD"|'''Olympus Corporation'''
|bgcolor = "#4F81BD"|
|-
|align = "center" bgcolor = "#DBE5F1"|'''Financial Year End'''
|bgcolor = "#DBE5F1"|March, 31st
|-
|align = "center" rowspan = "2"|'''Revenue'''
|2011: ¥847.10B / $10.58B
|-
|2010: ¥ 883.08B / $11.03B
|-
|align = "center" bgcolor = "#DBE5F1"|Revenue Change
|bgcolor = "#DBE5F1"|<nowiki>-</nowiki>4.07%
|-
|align = "center" rowspan = "2"|'''Operating Income'''
|2011: ¥35.4 B / $442M
|-
|2010: ¥60.1B / $751M
|-
|align = "center" bgcolor = "#DBE5F1"|Operating Income Change
|bgcolor = "#DBE5F1"|<nowiki>-</nowiki>41.10%
|-
|align = "center" rowspan = "2"|'''Net Profit'''
|2011: ¥7.38B / $92.25M
|-
|2010: ¥47.76B / $597M
|-
|align = "center" bgcolor = "#DBE5F1"|Net Profit Change
|bgcolor = "#DBE5F1"|<nowiki>-</nowiki>84.45%
|-
|align = "center" rowspan = "2"|'''R&D Expenses'''
|2011: ¥67.28B / $841M
|-
|2010: ¥61.85B / $773M
|-
|}
 
{|align="center"
|<gflash>1100 825 http://dolcera.com/upload/files/Revenue_Metrics.swf</gflash>
|-
|}
 
Source: SEC fillings

==Medical Systems==

The Medical Systems Business covers gastrointestinal endoscopes, surgical endoscopes, endotherapy devices, endoscopic ultrasound systems and medical information systems.
 
With an approximately 70% share, the Olympus group has secured a leading position in the global Gastrointestinal endoscopy market. Working to expand diagnostic coverage beyond the digestive system, the group is developing new equipment and new techniques ranging from diagnosis through treatment.
 
It's current research focus is on both minimally invasive treatment technology that reduces the burden on patients and product usability, for example, enhanced performance and functions to benefit doctors and technicians. The group's flagship products are equipped with a high-resolution endoscopic system and Narrow Band Imaging technology so that they can also support cancer diagnosis and treatment.
 

Medical systems business has the following business lines:
* '''Endoscopes''' Endoscopic video imaging systems, medical information systems, fiberscope systems, broncho endoscope systems, endoscopic ultrasound systems; ultrasound fiberscopes; ultrasound probes; ultrasound centers; ultrasound-guided needle puncture systems; cleaning, disinfecting and sterilization systems; medical treatment peripherals; ancillary products
* '''Endosurgery''' Endoscopy products for gastroenterological surgery, thoracic surgery, urology, gynecology, orthopedic surgery, neurosurgery, cardiovascular surgery, anesthesiology and otolaryngology; treatment and surgical equipment; peripherals
* '''Endotherapy''' Endotherapy products

===Revenue===
{|align="center"
|<gflash>900 600 http://dolcera.com/upload/files/Medical_Device_Segment.swf</gflash>
|-
|}
 
Source: SEC fillings
 
<nowiki>*</nowiki> MIP includes surgical endoscopes and treatment equipments.
*Medical systems segment has over 14,000 employees

===Projections for FY 2012===
Quarter 3
 

* In endoscopes, new shipments of some products (Lucera) have ground to a halt, but the company expects to see a rebound in 2H. For the year as a whole it projects endoscope sales will be down 5% YoY.
* The company estimates 1H sales in the medical systems division at JPY165bn (-6% YoY), and OP at JPY27bn; it projects 2H sales at JPY195bn (+8%) and OP at JPY43bn.
* In the medical systems division, new product launches are planned for both surgical endoscopes and energy devices (treatment tools).
* It projects sales of MIPs (surgical endoscopes, treatment equipment) at JPY180.5bn (+10% YoY). Sales in FY3/11 were flat YoY due mainly to the strength of the yen, but positive growth is expected this year.
* The company projects sales of gastrointestinal endoscopes at JPY164bn, -5% YoY, reflecting production setbacks in 1H.
* The earthquake’s impact has caused bottlenecks in purchasing of parts and materials for gastrointestinal endoscopes,leading to delays in product launches. In the latest telephone conference, the company offered no new information about timing. We believe there has been no real change from the company’s comments at the results briefing in May,and it remains to be seen whether the company will be able to launch its new products this fiscal year. The company’s FY3/12 earnings forecasts do not reflect any contribution from new products. Sales in the medical systems division got off to a slow start, falling short of projections in April-May.
 

==Endoscopes==

===Market Share===

[[Image:CoSHare1.PNG|centre|frame|Source: Espicom]]
 
The worldwide endoscopy market (comprising laparoscopy, gastro-intestinal, visualisation, arthroscopy and urology
products, rigid and flexible scopes, implants, surgical and other instruments) was worth approximately '''US$21.3 billion in 2009'''. Olympus’ share of this market was estimated to be 18%($3.834B), behind market leader Johnson & Johnson with an
approximate 21% market share. In third place was Covidien (13%), followed by Boston Scientific (7%), Stryker (4%), Smith &
Nephew (4%) and Karl Storz (4%).

===Product Portfolio===

[[Image:prodcuts_olympus.PNG|center|frame| [http://www.olympus-global.com/en/ Olympus]]]
 
In the medical equipment market, growth in the inspection device field has been stagnant, although such therapeutic device fields as surgical and endotherapy devices have shown market growth and drawn attention for technological innovation.
 
* The Exera 2, the previous entry in the Exera series, used NBI technology to enable full-color endoscopy, allowing doctors to more easily recognize affected areas in their patients. This product thus addressed doctors’ needs in the area of visibility, and sales grew worldwide.

==Gastrointestinal Endoscopy==

With an approximately 70% global market share for gastrointestinal endoscopes and an established position at the medical vanguard, Olympus maintains its passion for advancing technologies in response to doctors' needs
 

===Diagnosis and Treatment using Gastrointestinal Endoscopy===

'''Diagnosis'''
* Biopsy
* Cytodiagnosis
* Staining
 
'''Treatment'''
* Cancer (esophageal, stomach, colon, etc.)
* Varcies (esophageal)
* Foreign object retrieval ( esophagus, stomach)
* Hemostasis (stomach)
* Ployps (stomach, colon)
* Gallstones, bile duct stenosis (duodenum)

===Market Share===
[[Image:Coshare.PNG|center|frame|Source: Espicom]]
 
{|border="2" cellspacing="0" cellpadding="4" width="52%" align="center"
|bgcolor = "#4F81BD"|'''Company ( in Billion Yen)'''
|bgcolor = "#4F81BD"|'''2009'''
|bgcolor = "#4F81BD"|'''2010'''
|bgcolor = "#4F81BD"|'''2011'''
|-
|bgcolor = "#DBE5F1"|Olympus
|align = "right"| 212.89
|align = "right"| 191.94
|align = "right"| 195.45
|-
|bgcolor = "#DBE5F1"|FujiFilm HD
|align = "right"| 26.98
|align = "right"| 25.00
|align = "right"| 27.00
|-
|bgcolor = "#DBE5F1"|Hoya
|align = "right"| 48.87
|align = "right"| 47.00
|align = "right"| 45.00
|-
|}

===Products Offered===
 
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#4F81BD"|'''Speciality'''
|align = "center" bgcolor = "#4F81BD"|'''Details'''
|align = "center" bgcolor = "#4F81BD"|'''Picture'''
|align = "center" bgcolor = "#4F81BD"|'''Products'''
|-
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Gastroscopy'''
|bgcolor = "#DBE5F1"| Endoscopic examination, therapy or surgery of the interior of the stomach.
|[[Image:Gastroscope2.PNG|120px]] [[Image:Gastroscope.PNG|120px]] [[Image:Gastroscope1.PNG|120px]]
|
* GIF-H180J: Enables one to perform upper gastrointestinal endoscopy utilising the latest auxiliary water function and the sharpest possible image quality provided by High-resolution HDTV images featuring Narrow Band Imaging™ (NBI) and Close Focus
* GIF-H180: Delivers the best possible image quality for upper GI. High-resolution HDTV images in combination with Narrow Band Imaging (NBI) and Close Focus functionality
* GIF-XP180N: Ultra-slim upper gastrointestinal endoscopy with four-way angulation, NBI compatibility and a 5.5mm diameter distal end and insertion tube
* GIF-Q180: Features a short bending section as well as a reduced bending radius. Manoeuvrability and observation especially in the cardia region are enhanced.
* GIF-N180: The entire insertion tube measures just 4.9mm in diameter, resulting in improved insertability and the option for transnasal insertion in nearly 100 % of cases.
* GIF-Q165: Clear, sharp high-quality images in a large-size display and slim, 9.2 mm diameter distal end insertion tuber with wide 140° feild of view
* GIF-2T160: Two-channel endoscope for a variety of therapeutic applications
* GIF-XTQ160: Endoscope with powerful suction capabilities
* GIF-1TQ160: Endoscope with extended instrumentation capabilities
* GIF-Q160Z: Powerful 115 times magnification for detailed examination of the mucous surface
|-
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Duodenoscopy'''
|bgcolor = "#DBE5F1"| Endoscopic examination, therapy or surgery of the luminal surface of the duodenum
|[[Image:TJF-Q180V.PNG|100px]] [[Image:TJF-160VR.PNG|100px]]
|
* TJFQ180V: Provides critical visual feedback to enhance clinical decision making. In addition, a completely redesigned forceps elevator offers doctors the control needed when locking various sizes of guidewire. The unique dual locking function sets a new standard for ease-of-use and security during instrument exchange.
* TJF-160VR: Innovative V Groove forcep elevator offers reliable duodenoscopic treatment capability in combination with dedicated V-System ERCP devices
* TJF-145: Excellent treatment capability with extra-large 4.2mm channel - perfect for a wide range of endo-therapy accessories including stents.
* JF-140R: Facilitates introduction and manipulation of EndoTherapy accessories (for example papillotomes and ERCP catheters). The removable distal cap makes it possible to have access to all sides of the forceps elevator which can consequently be easily and quickly cleaned.
|-
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Colonoscopy'''
|bgcolor = "#DBE5F1"| Endoscopic examination, therapy or surgery of the luminal surface of the colon.
|[[Image:CF-180AI.PNG|100px]] [[Image:CQ-180AI.PNG|100px]] [[Image:CF-Q160DI.PNG|100px]]
|
* CF-H180AI/L: High-resolution HDTV images combined with the widest field of view ever available in a colonoscope: 170° lets you look even behind the folds potentially decreasing the miss-rate and improving orientation inside the colon.
* CF-Q180AI/L: The widest field of view ever available in a colonoscope: 170° lets you look even behind the folds potentially decreasing the miss-rate and improving orientation inside the colon.
* CF-Q160DI/L: ScopeGuide is a new Olympus product, which displays the shape and position of a colonoscope in real time throughout the examination without the use of x-rays. It based on magnetic fields generated by small coils build inside this endoscope and picked up by the antenna of ScopeGuide's main unit. From this data, the computer reconstructs a schematic picture of endoscope on the display.
* PCF-H180AI/L: Extra-slim colonoscope featuring outstanding high-resolution HDTV imaging and adjustable insertion characteristics
* CF-Q165I/L: Versatile colonoscope combining high image quality, large-size display and powerful treatment capability.
* CF-1T140I/L: For use in both therapeutic procedures and routine examinations, offers “graduated flexibility” for ease of insertion, and greater operational control and torque transmission to the distal end.
* CF-2T160I/L: Two-channel therapeutic capabilities
* CF-Q160ZI/L: Precision design that enables lens movement fully controlled via a connected magnification controller, which also provides foot switch operation. Powerful 150 times zoom magnification delivers detailed close-ups
|-
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Proctoscopy'''
|bgcolor = "#DBE5F1"| Endoscopic examination, therapy or surgery of the luminal surface of the rectum.
|[[Image:Procto.PNG|100px]]
|
* Rectal Diagnostic System: a complete line-up of instruments for rectoscopy, which have been especially designed for the diagnosis of possible disorders in the rectal region. Highest functionality combined with long-term durability distinguishes these instruments at reasonable investment costs.
* Transanal Endoscopic Microsurgery System: a versatile line up of transparent tubes enable clear inspection of the affected area. Access to a lesion is made easier by a "side window sheath". Fully compatible with standard VISERA equipment.
|-
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Enteroscopy'''
|bgcolor = "#DBE5F1"|Endoscopy of the small intestines accomplished while advancing the endoscope into the intestines from the stomach
|[[Image:Enteroscope1.png|100px]] [[Image:Enteroscope2.png|100px]]
|
* QuickClip2 Hemostatic Clip: Rotatable function provides better targeting capability . It's 9 mm clip opening is ideal for targeting lesions in the tight confines of the small bowel
* Injector Force Max Injection Needle: Kink-resistant sheath improves procedure efficiency and limits the occurrence of kinking in the depths of the small bowel.
* BiCOAG: Bipolar spiral tip allows effective coagulation at virtually any angle and centrally located flushing port allows for easy irrigation
* PolyLoop Ligating Loop: Proprietary ligating loop for prophylactic hemostasis
* Biopsy Forceps: Specially designed to minimize damage to the enteroscope with it's stainless steel construction.
|-
|}
 
Source: Company website

===New Products===
* '''Evis Lucera Colono-Videoscope:''' It helps in reducing the burden on patients and improving performance for both the inspection and treatment of colorectal cancer through the incorporation of two new functions, namely, high flexibility and highly responsive control at the insertion site, while adopting a thinner scope.
* '''Evis Lucera Gastrointestinal Videoscope:''' This slim gastrointestinal videoscope can be inserted through the nasal tract or the mouth to realise high quality images and is suited for the examination of lesions in the upper digestive tract, for example, in the stomach.
* '''Capsule Endoscopes:''' [[Image:Capsule.png|right|120px]] They are non-invasive, endoscopic imaging by use of VIDEO CAPSULE ENDOSCOPES to perform examination of the gastrointestinal tract, especially the small bowel. After being introduced in 2007, they have become a revolution. High-resolution imaging, real-time viewing, ease of use and proprietary hard and software make EndoCapsule a comprehensive and powerful system - redefining capsule endoscopy. One has to simply swallow the Endo capsule, a pill sized (11mm in external diameter and 26mm in length) capsule equipped with a tiny camera and lights, allows pictures to be taken of the entire small bowel. Endo capsule delivers high resolution images equivalent to those provided by endoscopes. EndoCapsule displays a clear and bright field of view for the fine observation of a variety of small bowel abnormalities. The Real Time Viewer enables the physician to test the proper functionality before the procedure and to confirm the location of the capsule in the GI tract during the process. In addition it is now possible to check whether and when the capsule has left the stomach. Product Details:[[Image:Capsule1.png|right|140px]]
** Supersensitive CCD
** Ultra compact lens
** Automatic Brightness Control adjusts illumination to maintain optimal imaging
** A wide depth of field provides superior observation
** 6 white LED lights always ensure a clear field of view
** Compact battery with energy efficient technology
The company is developing technologies to expand the application of capsule endoscopes to the stomach and large bowel.
 
Source: Company website, SEC fillings

==Recent Developments==
 
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#4F81BD"|'''S.No.'''
|align = "center" bgcolor = "#4F81BD"|'''Date'''
|align = "center" bgcolor = "#4F81BD"|'''News/Development'''
|-
|align = "right"|1.
|1st July 2011
|[http://www.olympus-global.com/en/news/2011b/nr110704spiruse.html Olympus Corporation to Acquire Spirus Medical, Inc., an endoscope insertion device manufacturer]
|-
|align = "right"|2.
|26th May 2011
|[http://www.olympus-global.com/en/news/2011a/nr110526awarde.html Narrow Band Imaging (NBI) endoscopic technology, useful in early cancer detection, selected for the Prime Minister Prize at the 2011 National Commendation for Invention]
|-
|align = "right"|3.
|24th May 2011
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=851 Olympus ScopeGuide Receives FDA Clearance]
|-
|align = "right"|4.
|6th April 2011
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=850 Olympus Names Luke Calcraft as President of Medical Systems Group in the Americas]
|-
|align = "right"|5.
|10th February 2011
|[http://www.olympus-global.com/en/news/2011a/nr110210corpe.html Olympus Names Michael C. Woodford to Serve as President]
|-
|align = "right"|6.
|25th October 2010
|[http://www.olympus-europa.com/corporate/1696_4717.htm Magnetically guided capsule endoscope system presented at UEGW in Barcelona]
|-
|align = "right"|7.
|26th May 2010
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=762 Olympus Develops World’s Fastest, Most Compatible Endoscope Reprocessor]
|-
|align = "right"|8.
|30th April 2010
|[http://www.olympus-europa.com/corporate/1696_4246.htm Olympus Medical Systems Corporation and Siemens Healthcare announce collaborative development of advanced magnetically guided capsule endoscope system for intragastric observation]
|-
|align = "right"|9.
|12th April 2010
|[http://www.olympus-global.com/en/news/2010a/nr100412omsiple.html Olympus Medical Systems India Private Limited established, would take care of Sales, marketing and service for medical equipment (endoscopes and related products, and surgical products, etc.)]
|-
|align = "right"|10.
|24th February 2010
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=745 Olympus Introduces HDTV Gastroscope with Auxiliary Water Channel]
|-
|align = "right"|11.
|10th November 2009
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=719 Olympus Introduces World's Smallest GI Scope to Offer 4-Way Angulation and Narrow Band Imaging]
|-
|align = "right"|12.
|23rd October 2009
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=713 Improved Endo Capsule Software Enhances Diagnostic Experience]
|-
|align = "right"|13.
|16th February 2009
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=662 Olympus Introduces World’s First Combined Endoscopic Ultrasound Processor for Imaging and Treatment of Digestive and Pulmonary Diseases]
|-
|align = "right"|14.
|11th December 2008
|[http://www.olympus-europa.com/corporate/1696_3032.htm Olympus further enhances credentials by entering into exclusive sales and distribution partnership with market and technology leader Advanced Surgical Concepts]
|-
|align = "right"|15.
|17th November 2008
|[http://www.olympus-europa.com/corporate/1696_2774.htm Olympus Medical Systems Europa and BrainLAB Sign Sales and Marketing Cooperation Agreement]
|-
|}

Heska Corporation

2011-09-16T14:00:12Z

Abhay.goel:

Go back to [http://dolcera.com/wiki/index.php?title=Veterinary_Vaccines_Market_Report#Company_Snapshot homepage]

{|border="2" cellspacing="0" cellpadding="4" width="60%" align="center"
|align = "center" bgcolor = "#4F81BD" colspan = "2"|'''Heska Corporation'''
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Financial Details'''
|-
|'''Total Company Revenue in 2010'''
|align = "center"|$ 654 Mn
|-
|'''Revenue from Animal Health Market in 2010'''
|align = "center"|$ 654 Mn
|-
|'''% of revenue from Animal Health in 2010'''
|align = "center"|100% (The company is only into Animal Health)
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Segmentwise Revenue Breakup ($ Mn)'''
|-
|'''Livestock Vaccines'''
|align = "center"|98
|-
|'''Companion Vaccines'''
|align = "center"|556
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Number of Major Vaccines (Animal-wise)'''
|-
|'''Poultry'''
|align = "center"|0
|-
|'''Swine'''
|align = "center"|0
|-
|'''Fish'''
|align = "center"|0
|-
|'''Sheep'''
|align = "center"|0
|-
|'''Cattle'''
|align = "center"|1
|-
|'''Canine'''
|align = "center"|0
|-
|'''Feline'''
|align = "center"|1
|-
|'''Equine'''
|align = "center"|0
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Future Focus Areas'''
|-
|'''Veterinary Vaccines under trial'''
|align = "center"|0
|-
|rowspan = "2"|'''Future Focus Areas of the company in the Veterinary Vaccines Market'''
|Core focus is on the canine and feline markets
|-
|Infectious disease vaccines, vaccine delivery technologies
|-
|}

 
Go back to [http://dolcera.com/wiki/index.php?title=Veterinary_Vaccines_Market_Report#Company_Snapshot homepage]

Boehringer Ingelheim Animal Health

2011-09-16T13:59:38Z

Abhay.goel:

Go back to [http://dolcera.com/wiki/index.php?title=Veterinary_Vaccines_Market_Report#Company_Snapshot homepage]

{|border="2" cellspacing="0" cellpadding="4" width="60%" align="center"
|align = "center" bgcolor = "#4F81BD" colspan = "2"|'''Boehringer Ingelheim Animal Health'''
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Financial Details'''
|-
|'''Total Company Revenue in 2010'''
|align = "center"|$ 5.06 Bn
|-
|'''Revenue from Animal Health Market in 2010'''
|align = "center"|$ 0.354 Bn
|-
|'''% of revenue from Animal Health in 2010'''
|align = "center"|6.99%
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Segmentwise Revenue Breakup ($ Bn)'''
|-
|'''Livestock Vaccines'''
|align = "center"|0.275
|-
|'''Companion Vaccines'''
|align = "center"|0.079
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Number of Major Vaccines (Animal-wise)'''
|-
|'''Poultry'''
|align = "center"|0
|-
|'''Swine'''
|align = "center"|7
|-
|'''Fish'''
|align = "center"|0
|-
|'''Sheep'''
|align = "center"|0
|-
|'''Cattle'''
|align = "center"|0
|-
|'''Canine'''
|align = "center"|0
|-
|'''Feline'''
|align = "center"|0
|-
|'''Equine'''
|align = "center"|2
|-
|bgcolor = "#95B3D7"|'''Mergers and Acquisitions (2009 - 2011)'''
|align = "center" bgcolor = "#95B3D7"|'''Consideration'''
|-
|'''Pfizer<nowiki>’</nowiki>s certain assets of Wyeth Pharmaceutical<nowiki>’</nowiki>s Fort Dodge Animal Health business'''
|align = "center"|undisclosed
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Future Focus Areas'''
|-
|'''Veterinary Vaccines under trial'''
|align = "center"|0
|-
|'''Future Focus Areas of the company in the Veterinary Vaccines Market'''
|Vaccines for the protection of swine and cattle
|-
|}

 
Go back to [http://dolcera.com/wiki/index.php?title=Veterinary_Vaccines_Market_Report#Company_Snapshot homepage]

Novartis Animal Health

2011-09-16T13:59:04Z

Abhay.goel:

Go back to [http://dolcera.com/wiki/index.php?title=Veterinary_Vaccines_Market_Report#Company_Snapshot homepage]

{|border="2" cellspacing="0" cellpadding="4" width="60%" align="center"
|align = "center" bgcolor = "#4F81BD" colspan = "2"|'''Novartis Animal Health'''
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Financial Details'''
|-
|'''Total Company Revenue in 2010'''
|align = "center"|$ 50.6 Bn
|-
|'''Revenue from Animal Health Market in 2010'''
|align = "center"|$ 0.5 Bn
|-
|'''% of revenue from Animal Health in 2010'''
|align = "center"|0.99%
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Segmentwise Revenue Breakup ($ Bn)'''
|-
|'''Livestock Vaccines'''
|align = "center"|0.375
|-
|'''Companion Vaccines'''
|align = "center"|0.125
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Number of Major Vaccines (Animal-wise)'''
|-
|'''Poultry'''
|align = "center"|0
|-
|'''Swine'''
|align = "center"|0
|-
|'''Fish'''
|align = "center"|2
|-
|'''Sheep'''
|align = "center"|0
|-
|'''Cattle'''
|align = "center"|1
|-
|'''Canine'''
|align = "center"|0
|-
|'''Feline'''
|align = "center"|0
|-
|'''Equine'''
|align = "center"|0
|-
|bgcolor = "#95B3D7"|'''Mergers and Acquisitions (2009 - 2011)'''
|align = "center" bgcolor = "#95B3D7"|'''Consideration'''
|-
|'''Chiron Behring Vaccines'''
|align = "center"|$ 22.3 Mn
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Future Focus Areas'''
|-
|'''Veterinary Vaccines under trial'''
|1 (Rabies Vaccine - Phase III)
|-
|'''Future Focus Areas of the company in the Veterinary Vaccines Market'''
|Want to increase their presence in vaccines
|-
|}

 
Go back to [http://dolcera.com/wiki/index.php?title=Veterinary_Vaccines_Market_Report#Company_Snapshot homepage]

Virbac

2011-09-16T13:58:31Z

Abhay.goel:

Go back to [http://dolcera.com/wiki/index.php?title=Veterinary_Vaccines_Market_Report#Company_Snapshot homepage]

{|border="2" cellspacing="0" cellpadding="4" width="60%" align="center"
|align = "center" bgcolor = "#4F81BD" colspan = "2"|'''Virbac'''
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Financial Details'''
|-
|'''Total Company Revenue in 2010'''
|align = "center"|$ 0.781 Bn
|-
|'''Revenue from Animal Health Market in 2010'''
|align = "center"|$ 0.781 Bn
|-
|'''% of revenue from Animal Health in 2010'''
|align = "center"|100% (The company is only into Animal Health)
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Segmentwise Revenue Breakup ($ Bn)'''
|-
|'''Livestock Vaccines'''
|align = "center"|0.294
|-
|'''Companion Vaccines'''
|align = "center"|0.469
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Number of Major Vaccines (Animal-wise)'''
|-
|'''Poultry'''
|align = "center"|0
|-
|'''Swine'''
|align = "center"|0
|-
|'''Fish'''
|align = "center"|0
|-
|'''Sheep'''
|align = "center"|0
|-
|'''Cattle'''
|align = "center"|0
|-
|'''Canine'''
|align = "center"|6
|-
|'''Feline'''
|align = "center"|2
|-
|'''Equine'''
|align = "center"|0
|-
|bgcolor = "#95B3D7"|'''Mergers and Acquisitions (2009 - 2011)'''
|align = "center" bgcolor = "#95B3D7"|'''Consideration'''
|-
|'''Santa Elena laboratory'''
|align = "center"|$ 3.7 Mn
|-
|'''Veterinary Assets from Pfizer Inc.'''
|align = "center"|undisclosed
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Future Focus Areas'''
|-
|'''Veterinary Vaccines under trial'''
|align = "center"|0
|-
|rowspan = "2"|'''Future Focus Areas of the company in the Veterinary Vaccines Market'''
|Bacterian and virus vaccines
|-
|Parasiticides and vaccines for cattle and sheep
|-
|}

 
Go back to [http://dolcera.com/wiki/index.php?title=Veterinary_Vaccines_Market_Report#Company_Snapshot homepage]

Bayer Healthcare - Animal Health

2011-09-16T13:57:53Z

Abhay.goel:

Go back to [http://dolcera.com/wiki/index.php?title=Veterinary_Vaccines_Market_Report#Company_Snapshot homepage]

{|border="2" cellspacing="0" cellpadding="4" width="60%" align="center"
|align = "center" bgcolor = "#4F81BD" colspan = "2"|'''Bayer Healthcare - Animal Health'''
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Financial Details'''
|-
|'''Total Company Revenue in 2010'''
|align = "center"|$ 12 Bn
|-
|'''Revenue from Animal Health Market in 2010'''
|align = "center"|$ 0.8 Bn
|-
|'''% of revenue from Animal Health in 2010'''
|align = "center"|6.67%
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Segmentwise Revenue Breakup ($ Bn)'''
|-
|'''Livestock Vaccines'''
|align = "center"|0.32
|-
|'''Companion Vaccines'''
|align = "center"|0.48
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Number of Major Vaccines (Animal-wise)'''
|-
|'''Poultry'''
|align = "center"|5
|-
|'''Swine'''
|align = "center"|13
|-
|'''Fish'''
|align = "center"|2
|-
|'''Sheep'''
|align = "center"|1
|-
|'''Cattle'''
|align = "center"|14
|-
|'''Canine'''
|align = "center"|4
|-
|'''Feline'''
|align = "center"|4
|-
|'''Equine'''
|align = "center"|5
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Future Focus Areas'''
|-
|'''Veterinary Vaccines under trial'''
|align = "center"|0
|-
|rowspan = "2"|'''Future Focus Areas of the company in the Veterinary Vaccines Market'''
|The Animal Health Division focuses its research and development activities on antimicrobials, parasiticides and active substances useful for the treatment of non-infectious diseases such as renal failure, pain management, oncology, and congestive heart failure
|-
|Parasitology and drug delivery systems, chewable drug admisitration technology (cats and dogs); innovative mastitis and reproduction products, injectable solutions and suspensions, intra-ruminal devices, and sheep, cattle and equine parasiticides;
|-
|}

There are no Mergers and Acquisitions by Bayer Healthcare in Veterinary Vaccines segment

 
Go back to [http://dolcera.com/wiki/index.php?title=Veterinary_Vaccines_Market_Report#Company_Snapshot homepage]

Sanofi-Aventis Animal Health

2011-09-16T13:57:14Z

Abhay.goel:

Go back to [http://dolcera.com/wiki/index.php?title=Veterinary_Vaccines_Market_Report#Company_Snapshot homepage]

{|border="2" cellspacing="0" cellpadding="4" width="60%" align="center"
|align = "center" bgcolor = "#4F81BD" colspan = "2"|'''Sanofi-Aventis Animal Health'''
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Financial Details'''
|-
|'''Total Company Revenue in 2010'''
|align = "center"|$ 30.384 Bn
|-
|'''Revenue from Animal Health Market in 2010'''
|align = "center"|$ 2.635 Bn
|-
|'''% of revenue from Animal Health in 2010'''
|align = "center"|8.67%
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Segmentwise Revenue Breakup ($ Bn)'''
|-
|'''Livestock Vaccines'''
|align = "center"|1.021
|-
|'''Companion Vaccines'''
|align = "center"|1.614
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Number of Major Vaccines (Animal-wise)'''
|-
|'''Poultry'''
|align = "center"|0
|-
|'''Swine'''
|align = "center"|0
|-
|'''Fish'''
|align = "center"|0
|-
|'''Sheep'''
|align = "center"|0
|-
|'''Cattle'''
|align = "center"|0
|-
|'''Canine'''
|align = "center"|3
|-
|'''Feline'''
|align = "center"|2
|-
|'''Equine'''
|align = "center"|2
|-
|bgcolor = "#95B3D7"|'''Mergers and Acquisitions (2009 - 2011)'''
|align = "center" bgcolor = "#95B3D7"|'''Consideration'''
|-
|'''Merial Ltd'''
|align = "center"|$ 4 Bn
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Future Focus Areas'''
|-
|'''Veterinary Vaccines under trial'''
|align = "center"|0
|-
|rowspan = "2"|'''Future Focus Areas of the company in the Veterinary Vaccines Market'''
|Viral and parasitological vaccines
|-
|In pharmaceutical R&D, we have 120 ongoing projects focusing on parasiticides, anti-infectives and internal medicine (endocrine/pain) and performance products. Meanwhile in biological R&D, we have 140 projects in progress focusing on zoonotic and emerging diseases, respiratory diseases, enteric diseases and enabling technologies.
|-
|}

 
Go back to [http://dolcera.com/wiki/index.php?title=Veterinary_Vaccines_Market_Report#Company_Snapshot homepage]

Merck Animal Health

2011-09-16T13:56:39Z

Abhay.goel:

Go back to [http://dolcera.com/wiki/index.php?title=Veterinary_Vaccines_Market_Report#Company_Snapshot homepage]

{|border="2" cellspacing="0" cellpadding="4" width="60%" align="center"
|align = "center" bgcolor = "#4F81BD" colspan = "2"|'''Merck Animal Health'''
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Financial Details'''
|-
|'''Total Company Revenue in 2010'''
|align = "center"|$ 46 Bn
|-
|'''Revenue from Animal Health Market in 2010'''
|align = "center"|$ 2.9 Bn
|-
|'''% of revenue from Animal Health in 2010'''
|align = "center"|6.30%
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Segmentwise Revenue Breakup ($ Bn)'''
|-
|'''Livestock Vaccines'''
|align = "center"|2.233
|-
|'''Companion Vaccines'''
|align = "center"|0.667
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Number of Major Vaccines (Animal-wise)'''
|-
|'''Poultry'''
|align = "center"|3
|-
|'''Swine'''
|align = "center"|1
|-
|'''Fish'''
|align = "center"|1
|-
|'''Sheep'''
|align = "center"|1
|-
|'''Cattle'''
|align = "center"|3
|-
|'''Canine'''
|align = "center"|1
|-
|'''Feline'''
|align = "center"|1
|-
|'''Equine'''
|align = "center"|2
|-
|bgcolor = "#95B3D7"|'''Mergers and Acquisitions (2009 - 2011)'''
|align = "center" bgcolor = "#95B3D7"|'''Consideration'''
|-
|'''Schering-Plough'''
|align = "center"|$ 41 Bn
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Future Focus Areas'''
|-
|'''Veterinary Vaccines under trial'''
|align = "center"|0
|-
|align = "center" rowspan = "3"|'''Future Focus Areas of the company in the Veterinary Vaccines Market'''
|Viral and parasitological vaccines
|-
|In pharmaceutical R&D, Merck has 120 ongoing projects focusing on parasiticides, anti-infectives and internal medicine (endocrine/pain) and performance products.
|-
|In biological R&D, Merck has 140 projects in progress focusing on zoonotic and emerging diseases, respiratory diseases, enteric diseases and enabling technologies.
|-
|}

 
Go back to [http://dolcera.com/wiki/index.php?title=Veterinary_Vaccines_Market_Report#Company_Snapshot homepage]

Pfizer Animal Health

2011-09-16T13:56:03Z

Abhay.goel:

Go back to [http://dolcera.com/wiki/index.php?title=Veterinary_Vaccines_Market_Report#Company_Snapshot homepage]

{|border="2" cellspacing="0" cellpadding="4" width="60%" align="center"
|align = "center" bgcolor = "#4F81BD" colspan = "2"|'''Pfizer Animal Health'''
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Financial Details'''
|-
|'''Total Company Revenue in 2010'''
|align = "center"|$ 67 Bn
|-
|'''Revenue from Animal Health Market in 2010'''
|align = "center"|$ 3.575 Bn
|-
|'''% of revenue from Animal Health in 2010'''
|align = "center"|5.34%
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Segmentwise Revenue Breakup ($ Bn)'''
|-
|'''Livestock Vaccines'''
|align = "center"|2.145
|-
|'''Companion Vaccines'''
|align = "center"|1.43
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Number of Major Vaccines (Animal-wise)'''
|-
|'''Poultry'''
|align = "center"|2
|-
|'''Swine'''
|align = "center"|4
|-
|'''Fish'''
|align = "center"|2
|-
|'''Sheep'''
|align = "center"|4
|-
|'''Cattle'''
|align = "center"|2
|-
|'''Canine'''
|align = "center"|16
|-
|'''Feline'''
|align = "center"|9
|-
|'''Equine'''
|align = "center"|1
|-
|bgcolor = "#95B3D7"|'''Mergers and Acquisitions (2009 - 2011)'''
|align = "center" bgcolor = "#95B3D7"|'''Consideration'''
|-
|'''Wyeth'''
|align = "center"|$ 68 Bn
|-
|'''Synbiotics Corp'''
|align = "center"|$ 735 Mn
|-
|'''RFCL-Vetnex Animal Health Unit'''
|align = "center"|$ 75 Mn
|-
|'''Microtek International Inc'''
|align = "center"|undisclosed
|-
|'''King Pharmaceuticals Inc'''
|align = "center"|$ 3.6 Bn
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Future Focus Areas'''
|-
|'''Veterinary Vaccines under trial'''
|0 (Innovative Vaccines in the last few years: 2 vaccines for dogs, 2 vaccines for swine, 1 for cattle)
|-
|rowspan = "2"|'''Future Focus Areas of the company in the Veterinary Vaccines Market'''
|Vaccines for emerging diseases such as blue-tongue, African horse sickness
|-
|Vaccines for dogs and cats
|-
|}

 
Go back to [http://dolcera.com/wiki/index.php?title=Veterinary_Vaccines_Market_Report#Company_Snapshot homepage]

File:Market Segmentation of Veterinary Vaccines1.jpg

2011-09-16T13:54:47Z

Abhay.goel:

File:Geographical Segmentation of Veterinary Vaccine Market1.jpg

2011-09-16T13:54:27Z

Abhay.goel:

File:Vaccines Market Size Forecast1.jpg

2011-09-16T13:54:10Z

Abhay.goel:

File:Global Vaccines Market Size1.jpg

2011-09-16T13:53:46Z

Abhay.goel:

Veterinary Vaccines Market Report

2011-09-16T13:52:35Z

Abhay.goel:

=Introduction=
Vaccination protects hundreds of millions of animals worldwide from disease and possibly death. Animals, just like humans, suffer from a range of infectious diseases. As veterinary medicine has advanced, prevention of disease has become a priority as healthy food comes from healthy animals. One of the best means of preventing disease is by creating immunity in the animal. This is usually achieved by vaccination.
 

Not all animals need every vaccine. Some, like clostridial disease prevention, are basically routine, just like childhood vaccination programmes. The vaccination programme chosen for farm animals depends on the management system, the location of the farm and the history of the herd or flock (and whether or not a disease is likely to be encountered). Most farm animals are young, and these animals (just like children) are often more susceptible to infection. So, for example, calves often need to be protected by vaccination against respiratory disease. Some of the diseases that can be prevented are shown below.
 
==Species Diseases Controlled by Vaccines==
# '''Cattle''' - Blackleg, tetanus, <nowiki>’</nowiki>husk<nowiki>’</nowiki> (lungworm disease), rotavirus, infectious bovine rhinotracheictis (IBR), respiratory syncytial virus, pasteurellosis, enteritis, leptospirosis, mastitis, ringworm, BVD, PI3, coronavirus, salmonella, E Coli.
# '''Sheep & goats''' - Clostridial diseases (8 different species including tetanus), pasteurellosis, ovine abortion (chlamydiosis and toxoplasmosis), louping ill, contagious pustular dermatitis (orf), footrot
# '''Pigs''' - Erysipelas, parvovirus, colibacillosis, clostridial disease, atrophic rhinitis, enteritis, porcine pneumonia, PRRS
# '''Poultry''' - Avian coccidiosis, avian encephalomyelitis, avian infectious bronchitis, avian infectious bursal disease, avian reovirus, chicken anaemia virus, duck virus enteritis, egg drop syndrome 1976, erysipelas, infectious laryngotracheitis, Marek<nowiki>’</nowiki>s disease, Newcastle disease, pasteurellosis, post-natal colibacillosis, salmonellosis, swollen head syndrome, turkey haemorrhagic enteritis, turkey rhinotracheitis
# '''Fish''' - Enteric redmouth disease, furunculosis, vibriosis (vibrio anguillarum, vibrio salmonicida and Vibrio viscosus (now named moratella viscosus))
# '''Dogs''' - Distemper, infectious canine hepatitis, leptospirosis, parvovirus, kennel cough (Bordetella bronchiseptica and canine parainfluenza virus). Also rabies for dogs going abroad as part of the PETS scheme.
# '''Cats''' - Feline infectious enteritis (or panleucopenia), feline leukaemia, chlamydia, cat <nowiki>’</nowiki>flu<nowiki>’</nowiki> (feline herpes virus and feline calicivirus). Also rabies for cats going abroad as part of the PETS scheme.
# '''Horses''' - Equine herpes virus 1, influenza, tetanus, viral arteritis. Also rabies (not routinely used in the UK)
# '''Rabbits''' - Myxomatosis, viral haemorrhagic disease
# '''Pigeons''' - Paramyxovirus, pigeon pox

Sources: National Office of Animal Health [http://www.noah.co.uk/issues/briefingdoc/10-vacci.htm 1],[http://www.noah.co.uk/issues/briefingdoc/22-vaccfarmanimals.htm 2]
 
 
=Market Overview=

The global pharmaceutical industry was $825Bn in 2010, out of which the total Vaccines market accounted for only 3.6% ($29.71 Bn). The vaccines market is classified in two segments: Human Vaccines and Veterinary Vaccines market. The human vaccines market accounts for more than 80% of the total vaccines market, whereas the Veterinary vaccines market accounts for around 20% of the total vaccines market. The focus of this report will be on Veterinary vaccines.
 
==Market Size of Vaccines==
* The global sales of human and animal vaccines were $22.5 Bn in 2008. In 2010, it has reached approximately $29.71 Bn. The global vaccines market grew at a compound annual growth rate (CAGR) of 14.91% in 2008-2010.
* The global market for human vaccines in 2008 was $18.7 Bn and, with a continuing increase in the global market, reached $5.48 Bn in 2010.
* The Veterinary vaccines market grew from approximately $3.8 Bn in 2008 to about $4.23 Bn in 2010, an increase of about 5.51%.

[[Image:Global Vaccines Market Size1.jpg|center|thumb|592px]]
 
Source: Dolcera Analysis

==Market Forecast for Vaccines==
* Veterinary Vaccines market is expected to increase at a 5.7% CAGR between 2010 and 2015 to reach $5.6 billion in 2015, driven by a growing number of diseases in animals, technological breakthroughs in biotechnology and growing awareness of animal disease
* Human Vaccines market is expected to grow at a CAGR) of 19.6% to reach $58.6 billion by the end of 2015.

[[Image:Vaccines Market Size Forecast1.jpg|center|thumb|601px]]
 
Source: Dolcera Analysis

==Geographical Segmentation of Veterinary Vaccines Market==

* United States represents the largest market for Veterinary vaccines worldwide, with the market share of 46% and market size of $1.94 Bn in 2010. The growth in the US Veterinary market will slow down in future due to safety concerns, higher market maturity and fewer prospects for mass production and development of new products.
* Europe comes second, with the market share of 33% and the market size of $1.4 Bn in 2010. The European market is mainly driven by the growing demand for livestock. 40% of the revenues in Europe come from France, Germany and United Kingdom, which amounts to $560 Mn

[[Image:Geographical Segmentation of Veterinary Vaccine Market1.jpg|center|thumb|600px]]
 
Source: Dolcera Analysis

==Market Segments of Veterinary Vaccines==
Veterinary Vaccines market is divided into 2 major segments: 
(i) Livestock Vaccines 
(ii) Companion Vaccines
 

* Livestock mainly consists of Farm animals like Cattle, pigs, sheep, poultry, aquaculture and bees.
* Companion Animals mainly consist of Dogs, cats and horses.
 
[[Image:Market Segmentation of Veterinary Vaccines1.jpg|center|thumb|591px]]
 
* '''Livestock Vaccines Market:'''
** Among the two segments analyzed, Livestock Vaccines accounts for the larger share of about 59% in 2010.
** Porcine vaccines are the largest sub-segment within Livestock Vaccines.
** The revenues from Porcine Vaccines market have touched $1 Bn in 2010.

* '''Companion Vaccines Market:'''
** Companion Vaccines account for 41% of the Veterinary Vaccines market in 2010.
** Companion Vaccines market is sub-divided into 3 segments, namely, Canine, Feline and Equine.
** Among these segments, Canine and Feline segments are large and account for 95% of the sales in Companion Vaccines.
** Equine vaccines only accounts for 5% of the sales in this segment.
** Canine vaccines are the fastest growing segment within Companion vaccines with the growth potential of more than 5% over the period to 2015.
 
Source: Dolcera Analysis

==Market Analysis of Veterinary Vaccines==
The following chart shows the percentage breakup of all the 5 segments in the Veterinary Vaccines market. It also shows the market forecast for each of the segments for the years 2010 - 2015. Please click on the required segment in the pie-chart to get the market forecast for that segment in the bar chart.

'''''Please click on the segments in the pie-chart to get the corresponding segment forecast for 2010-2015'''''
{|align = "center"
|<gflash>900 500 http://dolcera.com/upload/files/Market_Segment_Forecast.swf</gflash>
|-
|}
 

* Porcine vaccines are the largest sub-segment in the Veterinary Vaccines market which is forecasted to grow to $1.32 Bn market by 2015.
* Canine and Feline Vaccine markets are slightly behind the Porcine Vaccines market in terms of market size
* Canine Vaccines is the fastest growing segment among all the sub-segments with the growth rate of 5.81%
 
Source: Dolcera Analysis

=Major Players in the Veterinary Vaccines Market=
This section lists the top players in the Animal Health Segment based on the revenue generated in 2010. It then analyzes the performance of these players in the veterinary vaccines market by looking at the breakup of the revenues generated by them in the vaccines market, current product portfolio in veterinary vaccines, their R&D focus areas in this segment, veterinary vaccines under clinical trial and the benefits from mergers and acquisitions in this market.
 

== Key Players - on Revenue basis ==
Major Players in the Veterinary Vaccines market have been determined based on the revenues they made from Animal Health Segment in 2010. The following table lists down the top players in this market along with the revenues generated by them in Animal Health Segment in 2010. All the figures are in Billion $.

{|border="2" cellspacing="0" cellpadding="4" width="50%" align="center"
|bgcolor = "#4F81BD"|'''Company'''
|bgcolor = "#4F81BD"|'''Revenues from Animal Health in 2010 ($ Bn)'''
|-
|bgcolor = "#DBE5F1"|Pfizer
|align = "center" bgcolor = "#DBE5F1"|3.575
|-
|Merck
|align = "center"|2.9
|-
|bgcolor = "#DBE5F1"|Sanofi-Aventis
|align = "center" bgcolor = "#DBE5F1"|2.635
|-
|Bayer Healthcare
|align = "center"|0.8
|-
|bgcolor = "#DBE5F1"|Virbac
|align = "center" bgcolor = "#DBE5F1"|0.781
|-
|Novartis
|align = "center"|0.5
|-
|bgcolor = "#DBE5F1"|Boehringer Ingelheim
|align = "center" bgcolor = "#DBE5F1"|0.354
|-
|Heska Corporation
|align = "center"|0.0654
|-
|}
 

== Comparative Analysis of Key Players ==
The following interactive chart gives a snapshot of all the activities going on in the Veterinary Vaccines market. It gives the sales breakup for all the segments and sub-segments for all the major players in the Veterinary Vaccines market. It also lists down the area of clinical trials and future focus areas of all the major companies in this market.
 '''''Please click on the labels to get the corresponding information'''''

{|align = "center"
|<gflash>900 500 http://dolcera.com/upload/files/Comparative_Analysis3.swf</gflash>
|-
|}
# Pfizer is the market leader in the Veterinary vaccines market (by revenue) but Merck is the market leader in Livestock Vaccines market and Sanofi-Aventis is leading in the Companion Vaccines market.
# Livestock Vaccines market is more developed than Companion Vaccines market right now, but the later is catching up very quickly with more number of clinical trials in the Companion Vaccines area
# Two major areas of focus in the Veterinary vaccines market are:
#* Parasiticides
#* Infectious disease vaccines (Bacterian and Virus Vaccines)
 

== Company Snapshot ==
The following interactive graph compares all the major players in the veterinary vaccines market on various parameters

# [[Pfizer Animal Health]]
# [[Merck Animal Health]]
# [[Sanofi-Aventis Animal Health]]
# [[Bayer Healthcare - Animal Health]]
# [[Virbac]]
# [[Novartis Animal Health]]
# [[Boehringer Ingelheim Animal Health]]
# [[Heska Corporation]]
 

= Mergers and Acquisitions =
The following section lists down the major mergers and acquisitions in the veterinary vaccines market and their implications on the veterinary vaccines business of the corresponding companies. It then goes down to analyse one acquisition made in this segment, in detail.
 
== Major Mergers and Acquisitions ==
The following table lists down all the major mergers and acquisitions that took place in the last 2 years in the Veterinary Vaccines Market and the implications of the same, on the companies involved.

{|border="2" cellspacing="0" cellpadding="4" width="100%" align="center"
|bgcolor = "#4F81BD"|'''S.No'''
|bgcolor = "#4F81BD"|'''Date of Acquisition'''
|bgcolor = "#4F81BD"|'''Acquiring Company'''
|bgcolor = "#4F81BD"|'''Acquired Company/Business'''
|bgcolor = "#4F81BD"|'''Country'''
|bgcolor = "#4F81BD"|'''Implications to Veterinary Vaccines business of the Acquiring company/ merged companies'''
|bgcolor = "#4F81BD"|'''% Stake Purchased'''
|bgcolor = "#4F81BD"|'''Consideration ($ Mn)'''
|bgcolor = "#4F81BD"|'''Source'''
|-
|bgcolor = "#DBE5F1"|1
|bgcolor = "#DBE5F1"|29-Dec-10
|bgcolor = "#DBE5F1"|Pfizer
|bgcolor = "#DBE5F1"|Synbiotics Corp
|bgcolor = "#DBE5F1"|USA
|bgcolor = "#DBE5F1"|Synbiotics Corporation is a leader in the development, manufacture and marketing of immunodiagnostic tests for companion and food production animals. Pfizer Animal Health<nowiki>’</nowiki>s global reach, commercial operations, and expertise in regulatory and marketing functions will expand customer access to such leading products as WITNESS® and ASSURE® for companion animals, the SERELISA® franchise for livestock animals, and PROFLOK for poultry into new markets, especially in emerging markets for Synbiotics Corp. Marrying Synbiotics<nowiki>’</nowiki> R&D expertise in diagnostics with the strength of Pfizer veterinary R&D also is expected to help accelerate our diagnostic development program.
|bgcolor = "#DBE5F1"|undisclosed
|bgcolor = "#DBE5F1"|735
|bgcolor = "#DBE5F1"|[https://animalhealth.pfizer.com/sites/pahweb/PressReleases/Pages/Pfizer%20Animal%20Health%20To%20Acquire%20Synbiotics%20Corporation,%20Entering%20Diagnostics%20Sector.aspx Pfizer Press Release]
|-
|2
|14-Dec-10
|Novartis
|Chiron Behring Vaccines
|USA
|Chiron Behring is a joint venture of Novartis Vaccines and Diagnostics Inc. and Aventis Pharma. Novartis and Aventis are currently fighting a couple of cases on the largest selling rabies vaccine brand, Rabipur, after the brand went to Novartis in 2009. Rabipur was the largest selling rabies vaccine brand in India sold by Aventis for the last one decade. With this transaction, this dispute will be mutually settled. Rabipur, the top selling rabies vaccine, with an almost 60% vaccine share was contributing atleast 10% to Aventis Pharma<nowiki>’</nowiki>s total revenue till it went to Novartis
|49
|22.3
|[http://www.livemint.com/2010/12/14004955/Novartis-to-acquire-49-stake.html Livemint]
|-
|bgcolor = "#DBE5F1"|3
|bgcolor = "#DBE5F1"|11-Oct-10
|bgcolor = "#DBE5F1"|Pfizer
|bgcolor = "#DBE5F1"|King Pharmaceuticals Inc
|bgcolor = "#DBE5F1"|USA
|bgcolor = "#DBE5F1"|The transaction will further expand Pfizer<nowiki>’</nowiki>s business profile, including animal health business that will offer a variety of feed additive products for a wide range of species because of the acquisition
|bgcolor = "#DBE5F1"|100
|bgcolor = "#DBE5F1"|3600
|bgcolor = "#DBE5F1"|[http://www.bloomberg.com/news/2010-10-12/pfizer-agrees-to-purchase-king-pharmaceuticals-for-3-6-billion-in-cash.html Bloomberg]
|-
|4
|24-May-10
|Pfizer
|Microtek International Inc
|Canada
|Microtek International, Inc. is a recognized innovator in aquaculture vaccines, R&D and healthcare diagnostic services. The acquisition further expands Pfizer<nowiki>’</nowiki>s commitment to a safe food supply from healthy beef and dairy cattle, swine, poultry and fish. Microtek not only brings to Pfizer Animal Health industry-leading vaccines and technology, but also complements Pfizer<nowiki>’</nowiki>s portfolio of health services and diagnostics for food animal production
|undisclosed
|undisclosed
|[http://www.prnewswire.com/news-releases/pfizer-animal-health-expands-global-commitment-to-a-safe-food-supply-with-a-new-focus-on-healthy-fish-94817064.html PRNewsWire]
|-
|bgcolor = "#DBE5F1"|5
|bgcolor = "#DBE5F1"|5-Mar-10
|bgcolor = "#DBE5F1"|Virbac
|bgcolor = "#DBE5F1"|Santa Elena laboratory
|bgcolor = "#DBE5F1"|Uruguay
|bgcolor = "#DBE5F1"|Virbac wanted to establish a strategic alliance in the area of vaccines designed for food producing animals. This laboratory specializes in biotechnological products of aerobic and anaerobic fermentation for the manufacturing of bacterian vaccines (inactivated and modified),and a wide range of stable cell lines for the production of virus vaccines, inactivated or lessened. With this alliance, Santa Elena will be able to use the solid commercial platform brought by Virbac and introduce its vaccines range in many markets abroad. Virbac on its side will benefit from Santa Elena<nowiki>’</nowiki>s skills and know-how in biology to help building up a development and manufacturing base for food-producing animals vaccines, allowing Virbac<nowiki>’</nowiki>s entry into this market segment.
|bgcolor = "#DBE5F1"|30
|bgcolor = "#DBE5F1"|3.7
|bgcolor = "#DBE5F1"|[http://www.reuters.com/finance/stocks/VIRB.PA/key-developments/article/1836576 Reuters]
|-
|6
|12-Jan-10
|Virbac
|Veterinary Assets from Pfizer Inc.
|Australia
|Virbac SA will acquire rights to a portfolio of livestock products historically marketed in Australia by Fort Dodge Animal Health for use in farm animals, primarily cattle and sheep. The portfolio includes parasiticides (80% of sales) and vaccines (20%) that achieved net sales of approximately AUD 36 million in 2009. This new portfolio will perfectly fit and complement the current range of products that Virbac Australia is bringing to its customers.
|100
|undisclosed
|[http://in.reuters.com/finance/stocks/VIRB.PA/key-developments/article/1795141 Reuters]
|-
|bgcolor = "#DBE5F1"|7
|bgcolor = "#DBE5F1"|2-Nov-09
|bgcolor = "#DBE5F1"|Merck
|bgcolor = "#DBE5F1"|Schering-Plough
|bgcolor = "#DBE5F1"|USA
|bgcolor = "#DBE5F1"|This will double the number of drugs in late stages of development for Merck
|bgcolor = "#DBE5F1"|Merger (Merck shareholders would own 68% of the combined company)
|bgcolor = "#DBE5F1"|41,000
|bgcolor = "#DBE5F1"|[http://online.wsj.com/article/SB123659326420569463.html Wall Street Journal]
|-
|8
|14-Oct-09
|Pfizer
|Wyeth
|USA
|Wyeth acquisition will diversify Pfizer<nowiki>’</nowiki>s pipeline, particularly in vaccines and in biologics Pfizer Animal Health will now offer an enhanced portfolio in beef, dairy, and companion animals, as well as a redefined product line for swine, equine and poultry
|100
|68,000
|[http://www.reuters.com/article/2009/01/26/us-wyeth-pfizer-idUSTRE50M1AQ20090126?feedType=RSS Reuters]
|-
|bgcolor = "#DBE5F1"|9
|bgcolor = "#DBE5F1"|21-Sep-09
|bgcolor = "#DBE5F1"|Boehringer Ingelheim
|bgcolor = "#DBE5F1"|Pfizer<nowiki>’</nowiki>s certain assets of Wyeth Pharmaceutical<nowiki>’</nowiki>s Fort Dodge Animal Health business
|bgcolor = "#DBE5F1"|Several Countries
|bgcolor = "#DBE5F1"|The deal significantly increases the size of Boehringer Ingelheim<nowiki>’</nowiki>s companion animal and cattle portfolios. Boehringer Ingelheim will acquire the Duramune® line of vaccines for dogs, the Fel-O-Vax® line of vaccines for cats, and the Rabvac® line of rabies vaccines manufactured and sold in the U.S., Canada and Australia. In addition, a portfolio of pet and equine pharmaceutical products currently sold in the U.S. is also included in the deal. The company will also acquire cattle vaccines in the U.S. and Canada including the Triangle®, Pyramid, and Presponse® vaccine lines. Pharmaceutical products being acquired include Cydectin® (moxidectin) for cattle and sheep as well as Polyflex® (ampicillin sodium). The dairy portfolio includes the key brands Today® and Tomorrow®. Several Canadian swine vaccines are included in the acquisition as are some cattle vaccines sold in Europe and South Africa. It will build more capabilities in the core vaccine segment and expand Boehringer Ingelheim<nowiki>’</nowiki>s already strong product lines
|bgcolor = "#DBE5F1"|100
|bgcolor = "#DBE5F1"|undisclosed
|bgcolor = "#DBE5F1"|[http://www.americancattlemen.com/articles/boehringer-ingelheim-cattle-health Americancattlemen]
|-
|10
|17-Sep-09
|Sanofi-Aventis
|Merial Ltd (50% stake from Merck)
|USA
|Merial makes pet medicines like flea-and-tick blocker, Frontline and chewable heartworm preventer Heartgard, plus Ivomec, a parasite killer in cattle.
|100
|4,000
|[http://www.merck.com/newsroom/news-release-archive/corporate/2009_0918.html Merck Press Release]
|-
|bgcolor = "#DBE5F1"|11
|bgcolor = "#DBE5F1"|7-Jun-09
|bgcolor = "#DBE5F1"|Pfizer
|bgcolor = "#DBE5F1"|RFCL-Vetnex Animal Health Unit
|bgcolor = "#DBE5F1"|India
|bgcolor = "#DBE5F1"|Vetnex is a market leader in poultry, livestock and pet healthcare and is one of the top three players in the Indian animal healthcare market. Opportunity to enter India market
|bgcolor = "#DBE5F1"|100
|bgcolor = "#DBE5F1"|75
|bgcolor = "#DBE5F1"|[http://articles.economictimes.indiatimes.com/2009-06-09/news/28467472_1_rfcl-animal-healthcare-pfizer-animal-health Economic Times]
|-
|}
 

== Analysis of Pfizer's Acquisition of Wyeth==
{|border="2" cellspacing="0" cellpadding="4" width="30%" align="center"
|bgcolor = "#4F81BD"|'''Date of Acquisition'''
|14-Oct-09
|-
|bgcolor = "#4F81BD"|'''Acquiring Company'''
|Pfizer
|-
|bgcolor = "#4F81BD"|'''Acquired Company'''
|Wyeth
|-
|bgcolor = "#4F81BD"|'''Country'''
|USA
|-
|bgcolor = "#4F81BD"|'''Consideration'''
|$68 Bn
|-
|}
 

Post the acquisition, Pfizer Animal Health is now the world<nowiki>’</nowiki>s leader in the discovery, development, manufacture and sales of veterinary vaccines and medicines for livestock and companion animals.
 

=== Relevance to Pfizer Animal Health Business ===
Fort Dodge Animal Health is one of the divisions of Wyeth, which is a leader in the manufacturing of prescription and over-the-counter vaccines and pharmaceuticals for veterinary medicine as well as livestock.
 

=== Reasons for the acquisition ===
==== 1. Diversified its U.S. portfolio ====

The following products have been added to Pfizer Animal Health portfolio post acquisition:
* Beef and dairy animal health portfolio - FACTREL®, SYNOVEX®
* Swine market portfolio - SUVAXYN®, SUVAXYN PCV-2
* Poultry Health Portfolio - POULVAC®, MATERNAVAC® IBD-Reo
* Equine health portfolio - WEST NILE INNOVATOR ®, FLU VAC INNOVATOR ®, QUEST®, QUEST PLUS®
* Canine portfolio - LYMEVAX®
([http://www.equinechronicle.com/business/new-pfizer-animal-health-is-unveiled-with-acquisition-of-wyeth.html Source:Equinechronicle])
 
==== 2. Foray into new business areas ====
* Wyeth has expanded Pfizer's presence in animal health
* Augments in-line and pipeline portfolio in “invest to win” disease areas
* Enhances the scientific, manufacturing and pharmaceutical science capabilities of Pfizer
* Provides the best opportunities for world class, high performing talent in the industry
 
==== 3. Strengthens Platforms for Improved, Consistent and Stable Earnings Growth ====
* Pfizer’s CAGR before acquisition (2008-13)= -5.3%
* Wyeth’s CAGR before acquisition (2008-13)= 4.3%
* Combined Pfizer-Wyeth CAGR (2008-13) = 0.9%
* Wyeth contributes a large revenue increment to Pfizer
 
==== 4. Addresses Revenue Loss from Lipitor patent expiry ====
* Lipitor accounted for over 28% of Pfizer's sales in 2008
* Lipitor was going to lose US patent exclusivity in 2011, leading to significant revenue losses
* This acquisition makes up for the revenue loss from the exclusivity of Lipitor
 

=== Legal Issues due to the acquisition ===
The complaint charges that the proposed transaction likely would harm competition in each of the relevant markets by reducing the number of suppliers and leaving veterinarians and other animal health product customers with limited options. Without the competition provided by Pfizer and Wyeth in these markets, customers are more likely to see prices rise, according to the complaint. The complaint further alleges that the entry of new competitors in these markets would not be timely, likely, nor sufficient to offset the loss of competition, and that the transaction would increase the likelihood that Pfizer could act on its own or with other companies to raise prices.
 
==== Divesture of certain Animal Health Assets of Wyeth to Boehringer Ingelheim ====

Pfizer divested some of the Fort Dodge Animal Health products it acquired from Wyeth, within 10 days from the acquisition, to Boehringer Ingelheim to settle the anticompetitive effects the Federal Trade Commission believes are likely to result from the transaction in numerous markets for animal health products.

Due to this transaction, the Federal Trade Commission approved that it would not harm consumers in any prescription drug market where the companies currently overlap, reduce incentives to innovate, create intellectual property barriers, or allow Pfizer to engage in anticompetitive marketing.

([http://www.ftc.gov/opa/2009/10/pfizer.shtm Source: Federal Trade Commission])
 
= Emerging Trends in Veterinary Vaccines =
# Companion Veterinary Vaccines are trailing on high growth track
#* Livestock Vaccines market is more developed than Companion Vaccines market right now, but the later is catching up very quickly with more number of clinical trials in the Companion Vaccines area
#* In companion vaccines, canine vaccines is forecasted to grow at the highest pace and is expected to be the leading segment in the Veterinary Vaccines market
# Two major segments in focus:
#* Canine
#* Porcine
# Two major areas of focus in the Veterinary vaccines market are:
#* Parasiticides
#* Infectious disease vaccines (Bacteria and Virus Vaccines)

Main Page

2011-09-16T13:52:03Z

Abhay.goel: /* Business & Information Research Services */

__NOTOC__

[[#Intellectual Property (IP) Services|Intellectual Property(IP) Services]] 
[[#Business & Information Research Services|Business and Information Research Services]] 
[[#Dolcera Technology Platforms|Dolcera Technology Platform]]

== Intellectual Property (IP) Services ==
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"
|-
! style="background:lightgrey;width:50%" valign = "top" align = "left"|
===Life Sciences and Chemistry===
! style="background:lightgrey; width:50%" valign = "top" align = "left"|

===Technology===
|-
| valign = "top" |
 Landscape reports 
* [[Alopecia - Hair Loss]] | ([http://www.youtube.com/watch?v=jAIoyKuKQ6o Video])
* [[Inflammation and cardiovascular drugs]] | ([http://www.youtube.com/watch?v=FVUFcz2dpIM Video])
* [[RNAi Database sample wiki]] | ([http://www.youtube.com/watch?v=nsZLUSPn3cg Video])
* [[Choline Bitartarate]]
* [[Non-wovens]]
* [[Pressure sensitive adhesives]] | ([http://www.youtube.com/watch?v=plP3TzjYsiQ Video])
* [[Ureteral Stent]]
* [[Smart Drug Delivery Systems]] | ([http://www.youtube.com/watch?v=vARe9eBFsq4 Video])
* [[Silicone Hydrogel contact lens]]
* [[SC Johnson]]
* [[Pinene: An off flavor in mango juice]] | ([http://www.youtube.com/watch?v=P4fI1rjPjSg Video])
* [[Bio-PET]]
* [[Interferon For Treatment of Melanoma]]
* [[Antibody against TNF]]
* [[Pressure sensitive adhesives in packaging]]
| valign = "top" |

 Landscape reports 
* [[Hybrid Electric Vehicle Battery System]]
* [[Supply Chain RFID Applications]]
* [[Insurance sector]]
* [[CDMA Basics]]
* [[Quality of Service on CDMA platforms]]
* [[OLED - Organic Light Emitting Diode]]
* [[Carbon Nanotubes (CNT)]] | ([http://www.youtube.com/watch?v=HvZqBy8XvIE Video])
* [[Metallic and Ceramic construction materials]]
* [[Transactional memory]]
* [[Invalidation Search on a patent in the semiconductors space|Invalidation Search]]
* [[Golf Club Head Landscape]]
* [[Variable Valve Timing - Sample]]
* [[Wind Energy]]
|-
| valign = "top" |

STN Search Reports
* [[Markush Search Report]]

Dashboard
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard - live]
** ([[Alopecia Areata Dashboard Screenshots|Screenshots only]])
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]
* [[Legal Updates Demo|Legal updates dashboard]]
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=587 RNAi Dashboard]
| valign = "top" |

Dashboard
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=27 Automotive dashboard - live]
** [[Automotive Dashboard Screenshots|Screenshots only]]
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 WiMAX dashboard - live]
** [[WiMAX Dashboard Screenshots|Screenshots only]]
* [http://www.dolcera.com/ipmapdemo/rfid_model.swf RFID dashboard]

IP Valuation

*[[Holographic Image Display]]
|-
| valign = "top" |

Prior Art / Invalidation / FTO Search
* [http://dolcera.com/client/d8r3/hairloss_map.htm Alopecia/Hair loss IPMap]
* [[Markush Structure Search Sample]]
 Study: In re Bilski Impact
* [[In re Bilski Impact assessed from US PAIR Information]]
| valign = "top" |

Prior Art / Invalidation / FTO Search
* [[Prior Art Search Process]]
* [http://www.dolcera.com/ipmapdemo/satellite_antenna/ipmap.html Satellite Antenna IPMap]
* [http://www.dolcera.com/ipmapdemo/rfid/ipmap.html RFID IPMap]
* [http://www.dolcera.com/ipmapdemo/multimodal_apps/ipmap.html Multimodal Applications IPMap]
* [http://www.dolcera.com/ipmapdemo/Invalidation_US4825448.htm Invalidation Claim Chart Sample]
|-
|}

===Clinical Trial Database===
*[[Clinical Trial Database]]

== Business & Information Research Services ==
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"
|-
! style="background:lightgrey" valign=top width=50% align = "left"|
===Life Sciences and Chemistry===
! style="background:lightgrey" valign=top width=50% align = "left"|
===Technology===
|-
| valign=top |
* [[Diabetes products and services]]
* [[Drug Metabolism]]
* [[Toxicology]]
* [[Osteoporosis]]
* [[Oral Diabetes Drugs]]
* [[Ureteral Stent]]
* [[Premium Coffee Consumers Market Segmentation|Premium Coffee - Market Positioning]]
* [[Dolcera's Poster on Industrial Biotechnology|Industrial biotechnology]]
* [[OTC products for acne treatment]]
* [[Botox - from Medical Procedure to Household Word]]
* [[Digestive Remedies Market in India and China]]
* [[OTC vs. Prescription Drugs]]
* [[Rx to OTC Switch-Market Analysis]]
* [[Vaccines Market in Western Countries]], Company Profile:[http://dolcera.com/wiki/index.php?title=GlaxoSmithKline_profile GlaxoSmithKline]
* [[Ureteral Stent - Market Analysis]], Company Profile:[[Boston Scientific - Company Profile |Boston Scientific ]]
* [[Cardiac Pacemakers]]
* [[Olympus Corporation- Company Profile]]
* [[Veterinary Vaccines Market Report]]
| valign=top |
* [[4G wireless technology developments]]
* [[LTE]]
* [[Femtocells]]
* [[HDTV in the US]]
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics Innovation Explorer]
* [[Web video]]
* [[OLED Mobile Phones Market Research and Analysis Report]] | ([http://www.viddler.com/explore/dolcera/videos/6/ Video])
* [[Virtualization]]
* [[Cloud Computing]]
* [[Estimation of liquid carrying vehicles in USA]]
* [[A market study on Hybrid vehicles and the concept of V2G]]
* [[Patent Valuation]]

|-
! style="background:lightgrey" valign=top width=50% align = "left"|

===Finance===
! style="background:lightgrey" valign=top width=50% align = "left"|
===Others and CPG===
|-
| valign=top |
* [[Innovative personal finance products]]
* [[Life Insurance Industry in US]]
| valign=top |
*[[Deodorants Market Analysis: Acquisition of Sanex by Colgate]]
*[[Partner in sales planning]]

|}

== Dolcera Technology Platforms ==
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"
|-
| align = "top" |

==== Dashboard 1.1 ====
* [http://www.dolcera.com/auth/dashboarddemo/dashboard.php?workfilegroup_id=154 Demo Dashboard (Alopecia)]
** [[Access details]]
* [[Sample list of patent numbers]]
* [http://www.dolcera.com/auth/index.php Dashboard login page]

==== [[Workflow for creating a Dashboard]] ====

==== IP and Products dashboard ====
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard]
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]
* [[Legal Updates Demo|Legal updates dashboard]]
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 4G wireless product and patent dashboard]

==== Patent-pathway mapping ====
* [[Inflammation and cardiovascular drugs#Interactive signaling pathways and patents|Patent-pathway mapping]]
==== Sequence dashboard ====
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]

==== Design analysis ====
* [http://www.dolcera.com/website/demos/dental/main.html Dental Implant Design Analysis]

==== Innovation explorer ====
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics innovation explorer]
==== KPort ====
* [http://dolcera.com/website/demos/kport/main.html Collaboration Portal]

|-
|}

== Buy Dolcera Reports ==
* [[Landscape report for HEMT]]

Dolcera Offerings summary 
* [[Dolcera Offerings|Dolcera offerings summary]]

[[Technology Support]] 

Like any of these sample reports?
 '''These are sample reports with brief analysis''' 
'''Dolcera can provide a comprehensive report customized to your needs'''
{|border="2" cellspacing="0" cellpadding="4" align="center" "
|style="background:lightgrey" align = "center" colspan = "3"|'''[mailto:info@dolcera.com Buy the customized report from Dolcera]'''
|-
| align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]
|align = "center"| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]
|align = "center"| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]
|-
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]
|align = "center"| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]
|align = "center"| [http://www.dolcera.com/website_prod/industries Industry Focus]
|-
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]
|align = "center"| [http://www.dolcera.com/website_prod/tools Dolcera Tools]
|-
|}
 

----
{| style="border:1px solid #AAA; background:#E9E9E9" align="center"
|-
! style="background:lightgrey" | Contact Dolcera
|-
! style="background:lightgrey" | Samir Raiyani
|-
| '''Email''': [mailto:info@dolcera.com info@dolcera.com]
|-
| '''Phone''': +1-650-269-7952, +91-40-2355-3493
|}

Rx to OTC Switch-Market Analysis

2011-09-15T12:48:44Z

Abhay.goel: /* Objectives of the Survey */

==Introduction==

Over-the-counter (OTC) drugs are medicines that may be sold directly to a consumer without a prescription from a healthcare professional, and are commonly used to treat symptoms of common illnesses that may not require the direct supervision of a physician. 
*For a medicine to be granted OTC status, it must have a wide safety margin and be effective, and must bear understandable labeling to ensure proper use
*More than 700 OTC products on the market today use ingredients or dosages, that were available only by prescription, less than 30 years ago
*Rx to OTC switch refers to the transfer of proven prescription drugs (Rx) to non-prescription, over-the-counter (OTC) status. Rx to OTC switch is a data-driven, scientifically rigorous, and highly regulated process that allows consumers to have OTC access to a growing range of medicines
 
There are two ways in which drugs are commonly switched as approved by FDA in US :

#The OTC Drug Review
#*Began in 1972
#*Ongoing assessment of the safety and effectiveness of all nonprescription drugs
#*Panels of non-government experts review active ingredients in marketed OTC drug products to determine whether they can be classified as safe and effective
#*About 40 former prescription-only drug ingredients have been switched by this process
#New drug application (NDA) process
#*Manufacturers submit data to the FDA showing the drug is appropriate for self-administration.
#*The submission includes studies showing that the product's labeling can be read, understood, and followed by the consumer without the guidance of a health care provider
#*Some drugs are approved initially as OTC drugs, but most are first approved for prescription use and later switched to OTC

==Market Overview==
===OTC Market===
[[Image:OTC Market.png|center|thumb|900px|Source:Kalorama Information]]
{|border="2" align="center" cellspacing="0" cellpadding="4" width="28%"
|align = "center" bgcolor = "#8DB4E3"|'''Time Period'''
|align = "center" bgcolor = "#8DB4E3"|'''CAGR'''
|-
|align = "center"|2005-2009
|align = "center"|3.3%
|-
|align = "center"|2009-2014
|align = "center"|2.7%
|-
|align = "center"|2005-2014
|align = "center"|3.0%
|-
|}
 

===Rx vs. OTC Market===
'''Total Pharmaceutical Market by Country, 2009 ($B)'''
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#8DB4E3"|'''Country'''
|align = "center" bgcolor = "#8DB4E3"|'''Rx Market'''
|align = "center" bgcolor = "#8DB4E3"|'''OTC Market'''
|align = "center" bgcolor = "#8DB4E3"|'''Total Pharma Market'''
|align = "center" bgcolor = "#8DB4E3"|'''OTC as % of Total Pharma Market'''
|-
|align = "center" bgcolor = "#DBE5F1"|'''United States'''
|align = "center" bgcolor = "#DBE5F1"|214
|align = "center" bgcolor = "#DBE5F1"|18
|align = "center" bgcolor = "#DBE5F1"|232
|align = "center" bgcolor = "#DBE5F1"|'''7.8'''
|-
|align = "center"|'''Japan'''
|align = "center"|56
|align = "center"|11
|align = "center"|67
|align = "center"|'''16.4'''
|-
|align = "center"|'''Germany'''
|align = "center"|35
|align = "center"|5
|align = "center"|40
|align = "center"|'''12.5'''
|-
|align = "center"|'''France'''
|align = "center"|32
|align = "center"|4
|align = "center"|36
|align = "center"|'''11.1'''
|-
|align = "center"|'''China'''
|align = "center"|16
|align = "center"|5
|align = "center"|21
|align = "center"|'''23.1'''
|-
|align = "center"|'''United Kingdom'''
|align = "center"|17
|align = "center"|3
|align = "center"|20
|align = "center"|'''15.0'''
|-
|align = "center"|'''Russia'''
|align = "center"|13
|align = "center"|3
|align = "center"|16
|align = "center"|'''18.8'''
|-
|align = "center"|'''Brazil'''
|align = "center"|10
|align = "center"|2
|align = "center"|12
|align = "center"|'''16.7'''
|-
|align = "center"|'''Mexico'''
|align = "center"|9
|align = "center"|2
|align = "center"|11
|align = "center"|'''18.1'''
|-
|align = "center"|'''India'''
|align = "center"|6
|align = "center"|3
|align = "center"|9
|align = "center"|'''33.3'''
|-
|}
Source: Kalorama Information

===Rx to OTC Switches===
{|align="center"
|[[Image:Rx to OTC Switches market1.png|left|thumb|800px|Source:Kalorama Information]][[Image:Market Segmentation (2008).png|right|thumb|800px|Source:Kalorama Information]]
|-
|}
*CAGR for 2008-2013 is '''9.4%'''

===Major OTC Players===
[[Image:OTC Players1.png|center|thumb|800px|Source:Company Websites]]
 

===Sales Data for selected Rx to OTC Switches, USA===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#8DB4E3"|'''S.No'''
|align = "center" bgcolor = "#8DB4E3"|'''Switched Drug'''
|align = "center" bgcolor = "#8DB4E3"|'''Manufacturer/Marketer'''
|align = "center" bgcolor = "#8DB4E3"|'''Drug Category'''
|align = "center" bgcolor = "#8DB4E3"|'''Switch Year'''
|align = "center" bgcolor = "#8DB4E3"|'''First 12-Month Sales (in $M)'''
|-
|align = "center"|1
|align = "center"|Alli
|align = "center"|Glaxo SmithKline Consumer Healthcare
|align = "center"|Weight Loss Aid
|align = "center"|2007
|align = "center" bgcolor = "#DBE5F1"|80
|-
|align = "center"|2
|align = "center"|MiraLax
|align = "center"|Schering-Plough Healthcare
|align = "center"|Gastrointestinal
|align = "center"|2006
|align = "center" bgcolor = "#DBE5F1"|40
|-
|align = "center"|3
|align = "center"|Prilosec OTC
|align = "center"|Procter & Gamble
|align = "center"|Gastrointestinal
|align = "center"|2003
|align = "center" bgcolor = "#DBE5F1"|130
|-
|align = "center"|4
|align = "center"|Claritin
|align = "center"|Schering-Plough Healthcare
|align = "center"|Allergy
|align = "center"|2002
|align = "center" bgcolor = "#DBE5F1"|380
|-
|align = "center"|5
|align = "center"|Nicoderm CQ
|align = "center"|Glaxo SmithKline Consumer Healthcare
|align = "center"|Smoking Cessation
|align = "center"|1996
|align = "center" bgcolor = "#DBE5F1"|160
|-
|align = "center"|6
|align = "center"|Nicorette
|align = "center"|Glaxo SmithKline Consumer Healthcare
|align = "center"|Smoking Cessation
|align = "center"|1996
|align = "center" bgcolor = "#DBE5F1"|195
|-
|align = "center"|7
|align = "center"|Rogaine
|align = "center"|McNeil Consumer Healthcare
|align = "center"|Hair Loss
|align = "center"|1996
|align = "center" bgcolor = "#DBE5F1"|180
|-
|align = "center"|8
|align = "center"|Pepcid AC
|align = "center"|Johnson & Johnson- Merck Consumer Pharmaceuticals Co.
|align = "center"|Gastrointestinal
|align = "center"|1995
|align = "center" bgcolor = "#DBE5F1"|200
|-
|align = "center"|9
|align = "center"|Zantac 75
|align = "center"|Boehringer Ingelheim Consumer Healthcare Products
|align = "center"|Gastrointestinal
|align = "center"|1995
|align = "center" bgcolor = "#DBE5F1"|140
|-
|align = "center"|10
|align = "center"|Aleve
|align = "center"|Bayer Consumer Care
|align = "center"|Analgesic
|align = "center"|1994
|align = "center" bgcolor = "#DBE5F1"|110
|-
|}
Source:Company Websites, Press Releases and Journals

===Factors Affecting Rx to OTC Switch===
[[Image:Factors.png|center|thumb|800px]]

==Trends in Rx to OTC Switches==
===Rx-to-OTC Switches Since 2000===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#8DB4E3"|'''S.No'''
|align = "center" bgcolor = "#8DB4E3"|'''Ingredient'''
|align = "center" bgcolor = "#8DB4E3"|'''Product Category'''
|align = "center" bgcolor = "#8DB4E3"|'''Date of OTC Approval'''
|align = "center" bgcolor = "#8DB4E3"|'''Product Examples'''
|align = "center" bgcolor = "#8DB4E3"|'''Company'''
|-
|align = "center"|1
|align = "center"|ibuprofen (NDA)
|align = "center"|migraine
|align = "center"|25/02/2000
|align = "center"|Motrin Migraine Pain
|align = "center"|McNeil Consumer Healthcare
|-
|align = "center"|2
|align = "center" bgcolor = "#B8CCE4"|docosanol (NDA)
|align = "center" bgcolor = "#B8CCE4"|cold sore/fever blister
|align = "center" bgcolor = "#B8CCE4"|25/07/2000
|align = "center" bgcolor = "#B8CCE4"|Abreva Cream
|align = "center" bgcolor = "#B8CCE4"|Avanir Pharmaceuticals
|-
|align = "center" rowspan = "2"|3
|align = "center" bgcolor = "#B8CCE4"|famotidine, calcium carbonate,
|align = "center" bgcolor = "#B8CCE4"|heartburn,
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|17/10/2000
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|Pepcid Complete
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|J&J/Merck
|-
|align = "center" bgcolor = "#B8CCE4"|magnesium hydroxide (NDA)
|align = "center" bgcolor = "#B8CCE4"|acid indigestion
|-
|align = "center"|4
|align = "center"|butenafine hydrochloride (NDA)
|align = "center"|athlete's foot, jock itch, ringworm
|align = "center"|7/12/2001
|align = "center"|Lotrimin Ultra
|align = "center"|Schering-Plough
|-
|align = "center" rowspan = "2"|5
|align = "center"|ibuprofen, pseudoephedrine HCl,
|align = "center" rowspan = "2"|analgesic/decongestant
|align = "center" rowspan = "2"|18/04/2002
|align = "center" rowspan = "2"|Children’s Advil Cold
|align = "center" rowspan = "2"|Wyeth
|-
|align = "center"|suspension for pediatric use (NDA)
|-
|align = "center"|6
|align = "center" bgcolor = "#B8CCE4"|guaifenesin extended-release tablet (NDA)
|align = "center" bgcolor = "#B8CCE4"|expectorant
|align = "center" bgcolor = "#B8CCE4"|12/7/2002
|align = "center" bgcolor = "#B8CCE4"|Mucinex
|align = "center" bgcolor = "#B8CCE4"|Adams Respiratory Therapeutics
|-
|align = "center"|7
|align = "center" bgcolor = "#B8CCE4"|nicotine polacrilex troche/lozenge (NDA)
|align = "center" bgcolor = "#B8CCE4"|smoking cessation
|align = "center" bgcolor = "#B8CCE4"|31/10/2002
|align = "center" bgcolor = "#B8CCE4"|Commit
|align = "center" bgcolor = "#B8CCE4"|GlaxoSmithKline
|-
|align = "center"|8
|align = "center"|loratadine (NDA)
|align = "center"|antihistamine
|align = "center"|27/11/2002
|align = "center"|Claritin Tablets, Claritin RediTabs, Claritin Syrup
|align = "center"|Schering-Plough
|-
|align = "center" rowspan = "2"|9
|align = "center" rowspan = "2"|loratadine, pseudoephededrine sulfate (NDA)
|align = "center"|antihistamine/
|align = "center" rowspan = "2"|27/11/2002
|align = "center" rowspan = "2"|Claritin-D 12 Hour Extended Release Tablets,
|align = "center" rowspan = "2"|Schering-Plough
|-
|align = "center"|decongestant
|-
|align = "center"|10
|align = "center" bgcolor = "#B8CCE4"|omeprazole magnesium
|align = "center" bgcolor = "#B8CCE4"|acid reducer to treat frequent heartburn
|align = "center" bgcolor = "#B8CCE4"|20/06/2003
|align = "center" bgcolor = "#B8CCE4"|Prilosec OTC
|align = "center" bgcolor = "#B8CCE4"|Procter & Gamble
|-
|align = "center" rowspan = "2"|11
|align = "center" bgcolor = "#B8CCE4"|loratadine (NDA)
|align = "center" bgcolor = "#B8CCE4"|hives relief
|align = "center" bgcolor = "#B8CCE4"|15/11/2003
|align = "center" bgcolor = "#B8CCE4"|Claritin hives relief
|align = "center" bgcolor = "#B8CCE4"|Schering-Plough
|-
|align = "center"|diphenhydramine citrate & ibuprofen (NDA); diphenhydramine HCl & ibuprofen potassium (NDA)
|align = "center"|analgesic sleep-aid
|align = "center"|21/12/2005
|align = "center"|Advil PM
|align = "center"|Wyeth
|-
|align = "center"|12
|align = "center" bgcolor = "#B8CCE4"|ecamsule (combined with avobenzone and octocrylene (NDA)
|align = "center" bgcolor = "#B8CCE4"|sunscreen
|align = "center" bgcolor = "#B8CCE4"|21/07/2006
|align = "center" bgcolor = "#B8CCE4"|Anthelios SX
|align = "center" bgcolor = "#B8CCE4"|L’Oreal
|-
|align = "center" rowspan = "2"|13
|align = "center" bgcolor = "#CCC0DA"|levonorgestrel (NDA)
|align = "center" bgcolor = "#CCC0DA"|contraceptive
|align = "center" bgcolor = "#CCC0DA"|24/08/2006
|align = "center" bgcolor = "#CCC0DA"|Plan B
|align = "center" bgcolor = "#CCC0DA"|Duramed
|-
|align = "center" bgcolor = "#CCC0DA"|polyethylene glycol 3350 (NDA)
|align = "center" bgcolor = "#CCC0DA"|laxative
|align = "center" bgcolor = "#CCC0DA"|6/10/2006
|align = "center" bgcolor = "#CCC0DA"|MiraLAX
|align = "center" bgcolor = "#CCC0DA"|Schering-Plough
|-
|align = "center"|14
|align = "center"|ketotifen (NDA)
|align = "center"|antihistamine eye drops
|align = "center"|19/10/2006
|align = "center"|Zaditor
|align = "center"|Novartis
|-
|align = "center" rowspan = "2"|15
|align = "center" bgcolor = "#B8CCE4"|orlistat (NDA)
|align = "center" bgcolor = "#B8CCE4"|weight loss aid
|align = "center" bgcolor = "#B8CCE4"|7/2/2007
|align = "center" bgcolor = "#B8CCE4"|alli
|align = "center" bgcolor = "#B8CCE4"|GlaxoSmithKline
|-
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|cetirizine HCl & pseudoephedrine HCl (NDA)
|align = "center" bgcolor = "#B8CCE4"|antihistamine/
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|9/11/2007
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|Zyrtec-D
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|McNeil
|-
|align = "center"|16
|align = "center" bgcolor = "#B8CCE4"|decongestant
|-
|align = "center" rowspan = "2"|17
|align = "center" bgcolor = "#B8CCE4"|cetirizine HCl (NDA)
|align = "center" bgcolor = "#B8CCE4"|antihistamine, hives relief
|align = "center" bgcolor = "#B8CCE4"|16/11/2007
|align = "center" bgcolor = "#B8CCE4"|Zyrtec
|align = "center" bgcolor = "#B8CCE4"|McNeil
|-
|align = "center" bgcolor = "#CCC0DA" rowspan = "2"|lansoprazole (NDA)
|align = "center" bgcolor = "#CCC0DA"|acid reducer to treat
|align = "center" bgcolor = "#CCC0DA" rowspan = "2"|18/05/2009
|align = "center" bgcolor = "#CCC0DA" rowspan = "2"|Prevacid 24 HR
|align = "center" bgcolor = "#CCC0DA" rowspan = "2"|Novartis
|-
|align = "center"|18
|align = "center" bgcolor = "#CCC0DA"|frequent heartburn
|-
|align = "center" rowspan = "2"|19
|align = "center" bgcolor = "#CCC0DA"|levonorgestrel (NDA)
|align = "center" bgcolor = "#CCC0DA"|contraceptive
|align = "center" bgcolor = "#CCC0DA"|10/7/2009
|align = "center" bgcolor = "#CCC0DA"|Plan B One Step
|align = "center" bgcolor = "#CCC0DA"|Duramed
|-
|align = "center" bgcolor = "#B8CCE4"|omeprazole and sodium
|align = "center" bgcolor = "#B8CCE4"|acid reducer to treat
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|1/12/2009
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|Zegerid OTC
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|Schering-Plough
|-
|align = "center"|20
|align = "center" bgcolor = "#B8CCE4"|bicarbonate (NDA)
|align = "center" bgcolor = "#B8CCE4"|frequent heartburn
|-
|}

* Blue highlighted drugs are patent-protected 
* Purple highlighted drugs are under FDA exclusivity period

===Rx to OTC Switches before patent expiry===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#8DB4E3"|'''S.No'''
|align = "center" bgcolor = "#8DB4E3"|'''Product Examples'''
|align = "center" bgcolor = "#8DB4E3"|'''Company'''
|align = "center" bgcolor = "#8DB4E3"|'''Date of OTC Approval'''
|align = "center" bgcolor = "#8DB4E3"|'''Patent Expiry'''
|align = "center" bgcolor = "#8DB4E3"|'''FDA Exclusivity'''
|align = "center" bgcolor = "#8DB4E3"|'''Patent Number'''
|-
|align = "center"|1
|align = "center" |Abreva Cream
|align = "center" |Avanir Pharmaceuticals
|align = "center" |25/07/2000
|align = "center" |28/04/2014
|align = "center" |--
|align = "center" |4874794
|-
|align = "center"|2
|align = "center" |Pepcid Complete
|align = "center" |J&J/Merck
|align = "center" |17/10/2000
|align = "center" |15/10/2000
|align = "center" |--
|align = "center" |4283408
|-
|align = "center"|3
|align = "center" |Mucinex
|align = "center" |Adams Respiratory Therapeutics
|align = "center" |12/7/2002
|align = "center" |28/04/2020
|align = "center" |--
|align = "center" |6372252
|-
|align = "center"|4
|align = "center" |Commit
|align = "center" |GlaxoSmithKline
|align = "center" |31/10/2002
|align = "center" |21/08/2010
|align = "center" |--
|align = "center" |5110605
|-
|align = "center"|5
|align = "center" |Prilosec OTC
|align = "center" |Procter & Gamble
|align = "center" |20/06/2003
|align = "center" |15/11/2019
|align = "center" |--
|align = "center" |5690960, 5753265, 5817338, 5900424, 6403616, 6428810
|-
|align = "center"|6
|align = "center" |Claritin hives relief
|align = "center" |Schering-Plough
|align = "center" |15/11/2003
|align = "center" |19/06/2002
|align = "center" |--
|align = "center" |4282233
|-
|align = "center"|7
|align = "center" |Anthelios SX
|align = "center" |L’Oreal
|align = "center" |21/07/2006
|align = "center" |24/12/2013
|align = "center" |--
|align = "center" |5587150
|-
|align = "center"|8
|align = "center" bgcolor = "#CCC0DA"|Plan B
|align = "center" bgcolor = "#CCC0DA"|Duramed
|align = "center" bgcolor = "#CCC0DA"|24/08/2006
|align = "center" bgcolor = "#CCC0DA"|--
|align = "center" bgcolor = "#CCC0DA"|24/08/2009
|align = "center" bgcolor = "#CCC0DA"|<nowiki>-</nowiki>-
|-
|align = "center"|9
|align = "center" bgcolor = "#CCC0DA"|MiraLAX
|align = "center" bgcolor = "#CCC0DA"|Schering-Plough
|align = "center" bgcolor = "#CCC0DA"|6/10/2006
|align = "center" bgcolor = "#CCC0DA"|--
|align = "center" bgcolor = "#CCC0DA"|6/10/2009
|align = "center" bgcolor = "#CCC0DA"|<nowiki>-</nowiki>-
|-
|align = "center"|10
|align = "center" |alli
|align = "center" |GlaxoSmithKline
|align = "center" |7/2/2007
|align = "center" |6/1/2018
|align = "center" |7/2/2010
|align = "center" |6004996
|-
|align = "center"|11
|align = "center" |Zyrtec-D
|align = "center" |McNeil
|align = "center" |9/11/2007
|align = "center" |10/6/2022
|align = "center" |<nowiki>-</nowiki>-
|align = "center" |6469009, 6489329, 7014867, 7226614
|-
|align = "center"|12
|align = "center" |Zyrtec
|align = "center" |McNeil
|align = "center" |16/11/2007
|align = "center" |2/7/2018
|align = "center" |<nowiki>-</nowiki>-
|align = "center" |6455533
|-
|align = "center"|13
|align = "center" bgcolor = "#CCC0DA"|Prevacid 24 HR
|align = "center" bgcolor = "#CCC0DA"|Novartis
|align = "center" bgcolor = "#CCC0DA"|18/05/2009
|align = "center" bgcolor = "#CCC0DA"|--
|align = "center" bgcolor = "#CCC0DA"|18/05/2012
|align = "center" bgcolor = "#CCC0DA"|<nowiki>-</nowiki>-
|-
|align = "center"|14
|align = "center" bgcolor = "#CCC0DA"|Plan B One Step
|align = "center" bgcolor = "#CCC0DA"|Duramed
|align = "center" bgcolor = "#CCC0DA"|10/7/2009
|align = "center" bgcolor = "#CCC0DA"|--
|align = "center" bgcolor = "#CCC0DA"|10/7/2012
|align = "center" bgcolor = "#CCC0DA"|<nowiki>-</nowiki>-
|-
|align = "center"|15
|align = "center" |Zegerid OTC
|align = "center" |Schering-Plough
|align = "center" |1/12/2009
|align = "center" |15/07/2016
|align = "center" |<nowiki>-</nowiki>-
|align = "center" |6489346, 6645988, 6699885, 7399772
|-
|}

* Purple highlighted drugs are under FDA exclusivity period

===Trend Analysis===
#11 out of 22 recent drugs ('''50%''') which switched from Rx to OTC were '''patent protected'''
#4 out of 22 recent drugs ('''18.2%''') which switched from Rx to OTC were under '''FDA exclusivity period'''
#13 out of 22 recent drugs ('''59%''') were switched from Rx to OTC before their patent or FDA exclusivity expiry. 2 drugs switched after the expiry of patents
#6 out of these 13 drugs made a switch more than 10 years before expiry
#5 out of these 13 drugs made a switch between 3 to 10 years before expiry
 

===Potential Drugs for Rx-to-OTC Switch===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#8DB4E3"|'''S.No'''
|align = "center" bgcolor = "#8DB4E3"|'''Drug'''
|align = "center" bgcolor = "#8DB4E3"|'''Patent Expiry Date'''
|align = "center" bgcolor = "#8DB4E3"|'''Expected Switch Year'''
|align = "center" bgcolor = "#8DB4E3"|'''US Patent Numbers'''
|-
|align = "center"|1
|align = "center"|Allegra
|align = "center"|14/3/2017
|align = "center"|2012
|align = "center"|5578610, 6037353, 6187791, 6399632, 7138524
|-
|align = "center"|2
|align = "center"|Clarinex
|align = "center"|1/12/2018
|align = "center"|<nowiki>></nowiki>2013
|align = "center"| 6514520, 7211582, 7214683, 7214684
|-
|align = "center"|3
|align = "center"|Crestor
|align = "center"|17/6/2022
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|6858618, 6316460, 7030152, RE37314
|-
|align = "center"|4
|align = "center"|Lescol
|align = "center"|12/6/2012
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|5356896, 5354772,
|-
|align = "center"|5
|align = "center"|Lipitor
|align = "center"|8/1/2017
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|5969156, 4681893, 5273995, 5686104, 5969156, 6126971, RE40667
|-
|align = "center"|6
|align = "center"|Pravachol
|align = "center"|22/10/2014
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|5622985
|-
|align = "center"|7
|align = "center"|TriCor
|align = "center"|21/2/2023
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|7276249, 5145684, 6277405, 6375986 , 6652881, 7037529, 7041319, 7320802
|-
|align = "center"|8
|align = "center"|Vytorin
|align = "center"|25/4/2017
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|RE37721, 5846966,
|-
|align = "center"|9
|align = "center"|Zetia
|align = "center"|25/7/2022
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|7030106, 5846966, 7612058, RE37721
|-
|align = "center"|10
|align = "center"|AcipHex
|align = "center"|8/5/2013
|align = "center"|2013
|align = "center"|5045552
|-
|align = "center"|11
|align = "center"|Nexium
|align = "center"|25/11/2018
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|7411070, 5690960, 5714504, 5877192, 5900424, 6147103, 6166213, 6191148, 6369085, 6428810, 6875872
|-
|align = "center"|12
|align = "center"|Protonix
|align = "center"|30/3/2025
|align = "center"|2010
|align = "center"|7553498, 4758579, 7544370, 7550153
|-
|align = "center"|13
|align = "center"|Zofran
|align = "center"|7/12/2026
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|7544370, 4758579, 7550153, 7553498
|-
|align = "center"|14
|align = "center"|Propecia
|align = "center"|5/11/2013
|align = "center"|2011
|align = "center"|5571817, 5547957, 5886184
|-
|align = "center"|15
|align = "center"|Imitrex
|align = "center"|10/3/2014
|align = "center"|<nowiki>></nowiki>2010
|align = "center"|5554639, 5307953, 5705520
|-
|align = "center"|16
|align = "center"|Actonel
|align = "center"|10/12/2018
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|6165513, 5583122, 6096342
|-
|align = "center"|17
|align = "center"|Boniva
|align = "center"|2/9/2014
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|5662918, 4927814
|-
|align = "center"|18
|align = "center"|Fosamax
|align = "center"| 17/1/2019
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|6225294, 5462932, 5994329, 6015801
|-
|align = "center"|19
|align = "center"|Evista
|align = "center"|10/3/2017
|align = "center"|<nowiki>></nowiki>2014
|align = "center"| 6894064, 6797719, 6458811, 5393763, 5457117, 5478847, 5811120, 5972383, 6906086, RE38968, RE39049, RE39050
|-
|align = "center"|20
|align = "center"|Detrol
|align = "center"|11/5/2020
|align = "center"|<nowiki>></nowiki>2014
|align = "center"| 5382600, 6630162, 6770295, 6911217
|-
|align = "center"|21
|align = "center"|Ditropan
|align = "center"|22/11/2015
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|5674895, 5840754, 1 5912268, 6262115, 6919092
|-
|align = "center"|22
|align = "center"|Cialis
|align = "center"|26/4/2020
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|7182958, 5859006, 6140329, 6821975, 6943166
|-
|align = "center"|23
|align = "center"|Levitra
|align = "center"|31/10/2018
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|6362178, 7696206
|-
|align = "center"|24
|align = "center"|Viagra
|align = "center"|22/10/2019
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|6469012, 5250534
|-
|}
 
 
==US Market Survey - Physicians Preferences and Insights==
===Objectives of Survey===
* To find Physician preferences for OTC drugs in comparison to prescription drugs
* To find insights on OTC drugs market and usage
* To understand the effectiveness of different sources of marketing
===Research Methodology===
The research instrument used was a questionnaire survey administered to collect empirical data. The physician responses were kept confidential to encourage openness and disclosure. The respondents rated the questions on Yes or No, ticked the relevant choices from the options available and ranked the options on a numerical scale. All the responses were coded using a binary system logic and analysis was done to derive insights there after.
===Sample Size and Screening Criteria===
 
{|border="2" align = "center" cellspacing="0" cellpadding="4" width="35%"
|align = "center" bgcolor = "#8DB4E3"|'''Gender'''
|align = "center" bgcolor = "#8DB4E3"|'''Sample Size'''
|-
|align = "center"|Male
|align = "center"|18
|-
|align = "center"|Female
|align = "center"|2
|-
|align = "center" bgcolor = "#C5D9F1"|'''Total Physicians'''
|align = "center" bgcolor = "#C5D9F1"|'''20'''
|-
|}
 
{|border="2" align = "center" cellspacing="0" cellpadding="4" width="60%"
|align = "center" bgcolor = "#8DB4E3" colspan = "2"|'''Screening Criteria'''
|-
|align = "center"|Primary Medical Specialty
|align = "center"|General Physician/Family Practice
|-
|align = "center"|No. of years in practice
|align = "center"|10
|-
|align = "center"|No. of patients consulting per month
|align = "center"|150
|-
|}
 

===Survey Results===
*All the respondents would recommend an OTC drug for fever
*About 95% of the doctors feel that the usage of OTC drugs has increased in the past five years
*About 85% of them would do so for other minor ailments like cold/cough and acidity
[[Image:USFirst.png|center|thumb|800px]]
 
*Low cost, effective and easy availability are selected as the major factors that resulted in increased usage of OTC drugs
*All the respondents feel it is important to prescribe a drug that minimizes patients' out-of-pocket costs, while choosing between equally effective and safe medications
 
[[Image:US2.png|center|thumb|800px]]
*Advertisement is the major source of information on OTC drugs for most of the respondents
*Only 30% of respondents replied in positive when asked about permitting marketing executives to market OTC products through them
 
[[Image:US3.png|center|thumb|800px]]
*About 63% of the respondents reported the growth rate of OTC usage during 2005-2010 between 25% - 50% and equal percentage of respondents stated that patients are trusting OTC drugs more than they used to do before as the prime reason for the growth
{|align = "center"
|[[Image:US4.png|left|thumb|800px]][[Image:US5.png|right|thumb|800px]]
|-
|}
 
*Less than 50% of the patients are not prescribed OTC due to their medical history
[[Image:non pres due to medical history.jpg|center|thumb|800px]]
 
*The case of patients coming to the doctor due to side effects from OTC drugs happens once a month
*About 45% of the respondents feel that non-prescription of drugs is not a serious problem
{| align="center"
|[[Image:Seriousness of non-prescription1.jpg|left|thumb|488×299px]][[Image:side effects1.jpg|right|thumb|488×304px]]
|-
|}

 
*85% of the doctors feel that the information on the label of OTC drugs is sufficient for the patients, in order to take OTC medicines
*50% of the doctors feel that more OTC drugs should be included under Medicare/insurance coverage
 
 
'''The effective ranking of the ailments in the order of safety of available OTC drugs is as follows:'''
[[Image:effective ranking.jpg|center|thumb|800px]]
[[Media:Working of Effective Ranking & Scoring.xls| To see the calculation of the effective scores and effective ranking, click on this link]]

==Indian Market Survey - Physicians Preferences and Insights==
===Objectives of the Survey===

The reason for carrying out this research is to determine the scope of potential switch of prescription drugs to over the counter drugs in the Indian pharma industry. The study is particularly focused at the scope of making statins(a drug for reducing cholesterol level) available over-the-counter. The study aims to understand how successful a switch would be, and if it is safe for such drugs to be made available without prescription. The study also aims at determining the marketing pattern of over the counter drugs, and how it can be improved in future.

The objectives for the survey are :

* To understand the effectiveness of OTC drug marketing campaigns in India
* To understand the source of information for the OTC drugs among doctors
* To explore the potential of switch from Rx to OTC drugs
* To gauge the current prescription pattern of statins in India
* To identify if statins can be switched to OTC

===Research Methodology===
The research instrument used was a questionnaire survey administered to collect empirical data. The physician responses were kept confidential to encourage openness and disclosure. The respondents rated the questions on Yes or No, ticked the relevant choices from the options available and ranked the options on a numerical scale. All the responses were coded using a binary system logic and analysis was done to derive insights there after.

===Sample Size and Screening Criteria===
'''Screening Criteria'''
{|border="2" align = "center" cellspacing="0" cellpadding="4" width="60%"
|align = "center" bgcolor = "#8DB4E3" colspan = "2"|'''Screening Criteria'''
|-
|align = "center"|Medical Specialty
|align = "center"|General Physician, Consulting Physician, Gynaecologist, Dermatologist, Cardiologist, Pediatrician
|-
|align = "center"|No. of years in practice
|align = "center"|10
|-
|align = "center"|No. of patients consulting per month
|align = "center"|150
|-
|}

 

'''Sample Size'''
{|border="2" align = "center" cellspacing="0" cellpadding="4" width="25%" align = "center"
|align = "center" bgcolor = "#8DB4E3"|'''Gender'''
|align = "center" bgcolor = "#8DB4E3"|'''Sample Size'''
|-
|align = "center"|Male
|align = "center"|44
|-
|align = "center"|Female
|align = "center"|16
|-
|align = "center" bgcolor = "#C5D9F1"|'''Total Physicians'''
|align = "center" bgcolor = "#C5D9F1"|'''60'''
|-
|}
 

{|border="2" cellspacing="0" cellpadding="4" width="25%" align = "center"
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Medical Specialty-wise Breakup'''
|-
|General Physician
|align = "center"|17
|-
|Consulting Physician
|align = "center"|9
|-
|Gynecologist
|align = "center"|9
|-
|Dermatologist
|align = "center"|4
|-
|Cardiologist
|align = "center"|12
|-
|Pediatrician
|align = "center"|6
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Geographywise Breakup'''
|-
|Mumbai
|align = "center"|15
|-
|Hyderabad
|align = "center"|15
|-
|Delhi NCR
|align = "center"|14
|-
|Bangalore
|align = "center"|16
|-
|}
 

===Survey Results===
* 97% of the Indian doctors feel that the usage of OTC drugs has increased in the past 5 years
* Indian doctors feel that the usage of OTC drugs has increased by more than 50% in the past 5 years
* Ease in the availability of OTC drugs, Advertisements and Saving time are the major reasons for increase in the usage of OTC drugs
{|align = "center" width="100%"
|[[Image:Opinion on increased usage - India1.jpg|left|thumb|520px]][[Image:Reasons for increase in OTC Usage - India.jpg|right|thumb|520px]]
|-
|}
 
* Headache, Cold/Cough and acidity are the most common ailments for which physicians prefer giving an OTC drug
[[Image:Physician preferences for minor ailments - india.jpg|center|thumb|603px]]
 
* More than 80% of the patients are not prescribed OTC drugs beacuse of their prior medical history
[[Image:non pres due to medical history - india.jpg|center|thumb|619px]]
 
* Only 13% of the doctors feel that the information on the labels of OTC drugs is sufficient
* 98% of the doctors feel that drug-drug interactions might be a potential danger for OTC drugs
* 48% of the patients come once a month to doctor due to side effects caused by OTC drugs
[[Image:Patients coming due to side effects - India.jpg|center|thumb|554px]]
 
* 95% of the doctors feel that the problem of taking OTCs in India is serious
[[Image:Seriousness of taking otc - india.jpg|center|thumb|547px]]
 

'''The effective ranking of the ailments in the order of safety of available OTC drugs is as follows:'''
[[Image:effective ranking - india.jpg|center|thumb|800px]]
[[Media:Working of Effective Ranking & Scoring - India.xls| To see the calculation of the effective scores and effective ranking, click on this link]]
 

* 72% of the doctors see an opportunity for Rx-to-OTC switch in Indian pharma market
* Drugs relating to Vitamins, Antacids, Cuts, wounds and burns & Cold/Cough have a better potential to do well as an OTC drug
[[Image:category with better potential for switch - india.jpg|center|thumb|570px]]
 

'''Effectiveness of marketing campaigns'''
* Advertisements are a major source of information for Indians on OTC drugs
[[Image:Source of info - india.jpg|center|thumb|514px]]
 

* Only 23% of the doctors permit marketing executives to market OTC products through them
* Quality is the most important factor affecting the choice of a drug
[[Image:factor affecting choice of a drug - india.jpg|center|thumb|484px]]
 

'''Results on Statins'''
* More than 50% of the patients with high cholesteral level fall in the age group of 40-60 years
* 73% of the patients with high cholesteral level are prescribed Statin by doctors
{|align = "center" width = "90%"
|[[Image:age grp increased cholesterol - india1.jpg|left|thumb|485px]][[Image:drug prescribed for cholesterol - india1.jpg|right|thumb|485px]]
|-
|}
 
* Atrovastatin and Rosuvastatin are prescribed more than 90% of the times (whenever statins are prescribed) by doctors to patients with high cholesterol level
[[Image:prescribed statin - india.jpg|center|thumb|526px]]
 
* Sale and effectiveness of the drug, Manufacturer of the drug and Patient type are the major factors for choosing any type/brand of statin
[[Image:factors for choosing statin - india.jpg|center|thumb|565px]]
 
* Only 25% of the doctors feel that statins safe to be made available as OTC drugs for low- to-moderate risk group

Rx to OTC Switch-Market Analysis

2011-09-15T12:42:20Z

Abhay.goel: /* Survey Results */

==Introduction==

Over-the-counter (OTC) drugs are medicines that may be sold directly to a consumer without a prescription from a healthcare professional, and are commonly used to treat symptoms of common illnesses that may not require the direct supervision of a physician. 
*For a medicine to be granted OTC status, it must have a wide safety margin and be effective, and must bear understandable labeling to ensure proper use
*More than 700 OTC products on the market today use ingredients or dosages, that were available only by prescription, less than 30 years ago
*Rx to OTC switch refers to the transfer of proven prescription drugs (Rx) to non-prescription, over-the-counter (OTC) status. Rx to OTC switch is a data-driven, scientifically rigorous, and highly regulated process that allows consumers to have OTC access to a growing range of medicines
 
There are two ways in which drugs are commonly switched as approved by FDA in US :

#The OTC Drug Review
#*Began in 1972
#*Ongoing assessment of the safety and effectiveness of all nonprescription drugs
#*Panels of non-government experts review active ingredients in marketed OTC drug products to determine whether they can be classified as safe and effective
#*About 40 former prescription-only drug ingredients have been switched by this process
#New drug application (NDA) process
#*Manufacturers submit data to the FDA showing the drug is appropriate for self-administration.
#*The submission includes studies showing that the product's labeling can be read, understood, and followed by the consumer without the guidance of a health care provider
#*Some drugs are approved initially as OTC drugs, but most are first approved for prescription use and later switched to OTC

==Market Overview==
===OTC Market===
[[Image:OTC Market.png|center|thumb|900px|Source:Kalorama Information]]
{|border="2" align="center" cellspacing="0" cellpadding="4" width="28%"
|align = "center" bgcolor = "#8DB4E3"|'''Time Period'''
|align = "center" bgcolor = "#8DB4E3"|'''CAGR'''
|-
|align = "center"|2005-2009
|align = "center"|3.3%
|-
|align = "center"|2009-2014
|align = "center"|2.7%
|-
|align = "center"|2005-2014
|align = "center"|3.0%
|-
|}
 

===Rx vs. OTC Market===
'''Total Pharmaceutical Market by Country, 2009 ($B)'''
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#8DB4E3"|'''Country'''
|align = "center" bgcolor = "#8DB4E3"|'''Rx Market'''
|align = "center" bgcolor = "#8DB4E3"|'''OTC Market'''
|align = "center" bgcolor = "#8DB4E3"|'''Total Pharma Market'''
|align = "center" bgcolor = "#8DB4E3"|'''OTC as % of Total Pharma Market'''
|-
|align = "center" bgcolor = "#DBE5F1"|'''United States'''
|align = "center" bgcolor = "#DBE5F1"|214
|align = "center" bgcolor = "#DBE5F1"|18
|align = "center" bgcolor = "#DBE5F1"|232
|align = "center" bgcolor = "#DBE5F1"|'''7.8'''
|-
|align = "center"|'''Japan'''
|align = "center"|56
|align = "center"|11
|align = "center"|67
|align = "center"|'''16.4'''
|-
|align = "center"|'''Germany'''
|align = "center"|35
|align = "center"|5
|align = "center"|40
|align = "center"|'''12.5'''
|-
|align = "center"|'''France'''
|align = "center"|32
|align = "center"|4
|align = "center"|36
|align = "center"|'''11.1'''
|-
|align = "center"|'''China'''
|align = "center"|16
|align = "center"|5
|align = "center"|21
|align = "center"|'''23.1'''
|-
|align = "center"|'''United Kingdom'''
|align = "center"|17
|align = "center"|3
|align = "center"|20
|align = "center"|'''15.0'''
|-
|align = "center"|'''Russia'''
|align = "center"|13
|align = "center"|3
|align = "center"|16
|align = "center"|'''18.8'''
|-
|align = "center"|'''Brazil'''
|align = "center"|10
|align = "center"|2
|align = "center"|12
|align = "center"|'''16.7'''
|-
|align = "center"|'''Mexico'''
|align = "center"|9
|align = "center"|2
|align = "center"|11
|align = "center"|'''18.1'''
|-
|align = "center"|'''India'''
|align = "center"|6
|align = "center"|3
|align = "center"|9
|align = "center"|'''33.3'''
|-
|}
Source: Kalorama Information

===Rx to OTC Switches===
{|align="center"
|[[Image:Rx to OTC Switches market1.png|left|thumb|800px|Source:Kalorama Information]][[Image:Market Segmentation (2008).png|right|thumb|800px|Source:Kalorama Information]]
|-
|}
*CAGR for 2008-2013 is '''9.4%'''

===Major OTC Players===
[[Image:OTC Players1.png|center|thumb|800px|Source:Company Websites]]
 

===Sales Data for selected Rx to OTC Switches, USA===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#8DB4E3"|'''S.No'''
|align = "center" bgcolor = "#8DB4E3"|'''Switched Drug'''
|align = "center" bgcolor = "#8DB4E3"|'''Manufacturer/Marketer'''
|align = "center" bgcolor = "#8DB4E3"|'''Drug Category'''
|align = "center" bgcolor = "#8DB4E3"|'''Switch Year'''
|align = "center" bgcolor = "#8DB4E3"|'''First 12-Month Sales (in $M)'''
|-
|align = "center"|1
|align = "center"|Alli
|align = "center"|Glaxo SmithKline Consumer Healthcare
|align = "center"|Weight Loss Aid
|align = "center"|2007
|align = "center" bgcolor = "#DBE5F1"|80
|-
|align = "center"|2
|align = "center"|MiraLax
|align = "center"|Schering-Plough Healthcare
|align = "center"|Gastrointestinal
|align = "center"|2006
|align = "center" bgcolor = "#DBE5F1"|40
|-
|align = "center"|3
|align = "center"|Prilosec OTC
|align = "center"|Procter & Gamble
|align = "center"|Gastrointestinal
|align = "center"|2003
|align = "center" bgcolor = "#DBE5F1"|130
|-
|align = "center"|4
|align = "center"|Claritin
|align = "center"|Schering-Plough Healthcare
|align = "center"|Allergy
|align = "center"|2002
|align = "center" bgcolor = "#DBE5F1"|380
|-
|align = "center"|5
|align = "center"|Nicoderm CQ
|align = "center"|Glaxo SmithKline Consumer Healthcare
|align = "center"|Smoking Cessation
|align = "center"|1996
|align = "center" bgcolor = "#DBE5F1"|160
|-
|align = "center"|6
|align = "center"|Nicorette
|align = "center"|Glaxo SmithKline Consumer Healthcare
|align = "center"|Smoking Cessation
|align = "center"|1996
|align = "center" bgcolor = "#DBE5F1"|195
|-
|align = "center"|7
|align = "center"|Rogaine
|align = "center"|McNeil Consumer Healthcare
|align = "center"|Hair Loss
|align = "center"|1996
|align = "center" bgcolor = "#DBE5F1"|180
|-
|align = "center"|8
|align = "center"|Pepcid AC
|align = "center"|Johnson & Johnson- Merck Consumer Pharmaceuticals Co.
|align = "center"|Gastrointestinal
|align = "center"|1995
|align = "center" bgcolor = "#DBE5F1"|200
|-
|align = "center"|9
|align = "center"|Zantac 75
|align = "center"|Boehringer Ingelheim Consumer Healthcare Products
|align = "center"|Gastrointestinal
|align = "center"|1995
|align = "center" bgcolor = "#DBE5F1"|140
|-
|align = "center"|10
|align = "center"|Aleve
|align = "center"|Bayer Consumer Care
|align = "center"|Analgesic
|align = "center"|1994
|align = "center" bgcolor = "#DBE5F1"|110
|-
|}
Source:Company Websites, Press Releases and Journals

===Factors Affecting Rx to OTC Switch===
[[Image:Factors.png|center|thumb|800px]]

==Trends in Rx to OTC Switches==
===Rx-to-OTC Switches Since 2000===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#8DB4E3"|'''S.No'''
|align = "center" bgcolor = "#8DB4E3"|'''Ingredient'''
|align = "center" bgcolor = "#8DB4E3"|'''Product Category'''
|align = "center" bgcolor = "#8DB4E3"|'''Date of OTC Approval'''
|align = "center" bgcolor = "#8DB4E3"|'''Product Examples'''
|align = "center" bgcolor = "#8DB4E3"|'''Company'''
|-
|align = "center"|1
|align = "center"|ibuprofen (NDA)
|align = "center"|migraine
|align = "center"|25/02/2000
|align = "center"|Motrin Migraine Pain
|align = "center"|McNeil Consumer Healthcare
|-
|align = "center"|2
|align = "center" bgcolor = "#B8CCE4"|docosanol (NDA)
|align = "center" bgcolor = "#B8CCE4"|cold sore/fever blister
|align = "center" bgcolor = "#B8CCE4"|25/07/2000
|align = "center" bgcolor = "#B8CCE4"|Abreva Cream
|align = "center" bgcolor = "#B8CCE4"|Avanir Pharmaceuticals
|-
|align = "center" rowspan = "2"|3
|align = "center" bgcolor = "#B8CCE4"|famotidine, calcium carbonate,
|align = "center" bgcolor = "#B8CCE4"|heartburn,
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|17/10/2000
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|Pepcid Complete
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|J&J/Merck
|-
|align = "center" bgcolor = "#B8CCE4"|magnesium hydroxide (NDA)
|align = "center" bgcolor = "#B8CCE4"|acid indigestion
|-
|align = "center"|4
|align = "center"|butenafine hydrochloride (NDA)
|align = "center"|athlete's foot, jock itch, ringworm
|align = "center"|7/12/2001
|align = "center"|Lotrimin Ultra
|align = "center"|Schering-Plough
|-
|align = "center" rowspan = "2"|5
|align = "center"|ibuprofen, pseudoephedrine HCl,
|align = "center" rowspan = "2"|analgesic/decongestant
|align = "center" rowspan = "2"|18/04/2002
|align = "center" rowspan = "2"|Children’s Advil Cold
|align = "center" rowspan = "2"|Wyeth
|-
|align = "center"|suspension for pediatric use (NDA)
|-
|align = "center"|6
|align = "center" bgcolor = "#B8CCE4"|guaifenesin extended-release tablet (NDA)
|align = "center" bgcolor = "#B8CCE4"|expectorant
|align = "center" bgcolor = "#B8CCE4"|12/7/2002
|align = "center" bgcolor = "#B8CCE4"|Mucinex
|align = "center" bgcolor = "#B8CCE4"|Adams Respiratory Therapeutics
|-
|align = "center"|7
|align = "center" bgcolor = "#B8CCE4"|nicotine polacrilex troche/lozenge (NDA)
|align = "center" bgcolor = "#B8CCE4"|smoking cessation
|align = "center" bgcolor = "#B8CCE4"|31/10/2002
|align = "center" bgcolor = "#B8CCE4"|Commit
|align = "center" bgcolor = "#B8CCE4"|GlaxoSmithKline
|-
|align = "center"|8
|align = "center"|loratadine (NDA)
|align = "center"|antihistamine
|align = "center"|27/11/2002
|align = "center"|Claritin Tablets, Claritin RediTabs, Claritin Syrup
|align = "center"|Schering-Plough
|-
|align = "center" rowspan = "2"|9
|align = "center" rowspan = "2"|loratadine, pseudoephededrine sulfate (NDA)
|align = "center"|antihistamine/
|align = "center" rowspan = "2"|27/11/2002
|align = "center" rowspan = "2"|Claritin-D 12 Hour Extended Release Tablets,
|align = "center" rowspan = "2"|Schering-Plough
|-
|align = "center"|decongestant
|-
|align = "center"|10
|align = "center" bgcolor = "#B8CCE4"|omeprazole magnesium
|align = "center" bgcolor = "#B8CCE4"|acid reducer to treat frequent heartburn
|align = "center" bgcolor = "#B8CCE4"|20/06/2003
|align = "center" bgcolor = "#B8CCE4"|Prilosec OTC
|align = "center" bgcolor = "#B8CCE4"|Procter & Gamble
|-
|align = "center" rowspan = "2"|11
|align = "center" bgcolor = "#B8CCE4"|loratadine (NDA)
|align = "center" bgcolor = "#B8CCE4"|hives relief
|align = "center" bgcolor = "#B8CCE4"|15/11/2003
|align = "center" bgcolor = "#B8CCE4"|Claritin hives relief
|align = "center" bgcolor = "#B8CCE4"|Schering-Plough
|-
|align = "center"|diphenhydramine citrate & ibuprofen (NDA); diphenhydramine HCl & ibuprofen potassium (NDA)
|align = "center"|analgesic sleep-aid
|align = "center"|21/12/2005
|align = "center"|Advil PM
|align = "center"|Wyeth
|-
|align = "center"|12
|align = "center" bgcolor = "#B8CCE4"|ecamsule (combined with avobenzone and octocrylene (NDA)
|align = "center" bgcolor = "#B8CCE4"|sunscreen
|align = "center" bgcolor = "#B8CCE4"|21/07/2006
|align = "center" bgcolor = "#B8CCE4"|Anthelios SX
|align = "center" bgcolor = "#B8CCE4"|L’Oreal
|-
|align = "center" rowspan = "2"|13
|align = "center" bgcolor = "#CCC0DA"|levonorgestrel (NDA)
|align = "center" bgcolor = "#CCC0DA"|contraceptive
|align = "center" bgcolor = "#CCC0DA"|24/08/2006
|align = "center" bgcolor = "#CCC0DA"|Plan B
|align = "center" bgcolor = "#CCC0DA"|Duramed
|-
|align = "center" bgcolor = "#CCC0DA"|polyethylene glycol 3350 (NDA)
|align = "center" bgcolor = "#CCC0DA"|laxative
|align = "center" bgcolor = "#CCC0DA"|6/10/2006
|align = "center" bgcolor = "#CCC0DA"|MiraLAX
|align = "center" bgcolor = "#CCC0DA"|Schering-Plough
|-
|align = "center"|14
|align = "center"|ketotifen (NDA)
|align = "center"|antihistamine eye drops
|align = "center"|19/10/2006
|align = "center"|Zaditor
|align = "center"|Novartis
|-
|align = "center" rowspan = "2"|15
|align = "center" bgcolor = "#B8CCE4"|orlistat (NDA)
|align = "center" bgcolor = "#B8CCE4"|weight loss aid
|align = "center" bgcolor = "#B8CCE4"|7/2/2007
|align = "center" bgcolor = "#B8CCE4"|alli
|align = "center" bgcolor = "#B8CCE4"|GlaxoSmithKline
|-
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|cetirizine HCl & pseudoephedrine HCl (NDA)
|align = "center" bgcolor = "#B8CCE4"|antihistamine/
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|9/11/2007
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|Zyrtec-D
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|McNeil
|-
|align = "center"|16
|align = "center" bgcolor = "#B8CCE4"|decongestant
|-
|align = "center" rowspan = "2"|17
|align = "center" bgcolor = "#B8CCE4"|cetirizine HCl (NDA)
|align = "center" bgcolor = "#B8CCE4"|antihistamine, hives relief
|align = "center" bgcolor = "#B8CCE4"|16/11/2007
|align = "center" bgcolor = "#B8CCE4"|Zyrtec
|align = "center" bgcolor = "#B8CCE4"|McNeil
|-
|align = "center" bgcolor = "#CCC0DA" rowspan = "2"|lansoprazole (NDA)
|align = "center" bgcolor = "#CCC0DA"|acid reducer to treat
|align = "center" bgcolor = "#CCC0DA" rowspan = "2"|18/05/2009
|align = "center" bgcolor = "#CCC0DA" rowspan = "2"|Prevacid 24 HR
|align = "center" bgcolor = "#CCC0DA" rowspan = "2"|Novartis
|-
|align = "center"|18
|align = "center" bgcolor = "#CCC0DA"|frequent heartburn
|-
|align = "center" rowspan = "2"|19
|align = "center" bgcolor = "#CCC0DA"|levonorgestrel (NDA)
|align = "center" bgcolor = "#CCC0DA"|contraceptive
|align = "center" bgcolor = "#CCC0DA"|10/7/2009
|align = "center" bgcolor = "#CCC0DA"|Plan B One Step
|align = "center" bgcolor = "#CCC0DA"|Duramed
|-
|align = "center" bgcolor = "#B8CCE4"|omeprazole and sodium
|align = "center" bgcolor = "#B8CCE4"|acid reducer to treat
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|1/12/2009
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|Zegerid OTC
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|Schering-Plough
|-
|align = "center"|20
|align = "center" bgcolor = "#B8CCE4"|bicarbonate (NDA)
|align = "center" bgcolor = "#B8CCE4"|frequent heartburn
|-
|}

* Blue highlighted drugs are patent-protected 
* Purple highlighted drugs are under FDA exclusivity period

===Rx to OTC Switches before patent expiry===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#8DB4E3"|'''S.No'''
|align = "center" bgcolor = "#8DB4E3"|'''Product Examples'''
|align = "center" bgcolor = "#8DB4E3"|'''Company'''
|align = "center" bgcolor = "#8DB4E3"|'''Date of OTC Approval'''
|align = "center" bgcolor = "#8DB4E3"|'''Patent Expiry'''
|align = "center" bgcolor = "#8DB4E3"|'''FDA Exclusivity'''
|align = "center" bgcolor = "#8DB4E3"|'''Patent Number'''
|-
|align = "center"|1
|align = "center" |Abreva Cream
|align = "center" |Avanir Pharmaceuticals
|align = "center" |25/07/2000
|align = "center" |28/04/2014
|align = "center" |--
|align = "center" |4874794
|-
|align = "center"|2
|align = "center" |Pepcid Complete
|align = "center" |J&J/Merck
|align = "center" |17/10/2000
|align = "center" |15/10/2000
|align = "center" |--
|align = "center" |4283408
|-
|align = "center"|3
|align = "center" |Mucinex
|align = "center" |Adams Respiratory Therapeutics
|align = "center" |12/7/2002
|align = "center" |28/04/2020
|align = "center" |--
|align = "center" |6372252
|-
|align = "center"|4
|align = "center" |Commit
|align = "center" |GlaxoSmithKline
|align = "center" |31/10/2002
|align = "center" |21/08/2010
|align = "center" |--
|align = "center" |5110605
|-
|align = "center"|5
|align = "center" |Prilosec OTC
|align = "center" |Procter & Gamble
|align = "center" |20/06/2003
|align = "center" |15/11/2019
|align = "center" |--
|align = "center" |5690960, 5753265, 5817338, 5900424, 6403616, 6428810
|-
|align = "center"|6
|align = "center" |Claritin hives relief
|align = "center" |Schering-Plough
|align = "center" |15/11/2003
|align = "center" |19/06/2002
|align = "center" |--
|align = "center" |4282233
|-
|align = "center"|7
|align = "center" |Anthelios SX
|align = "center" |L’Oreal
|align = "center" |21/07/2006
|align = "center" |24/12/2013
|align = "center" |--
|align = "center" |5587150
|-
|align = "center"|8
|align = "center" bgcolor = "#CCC0DA"|Plan B
|align = "center" bgcolor = "#CCC0DA"|Duramed
|align = "center" bgcolor = "#CCC0DA"|24/08/2006
|align = "center" bgcolor = "#CCC0DA"|--
|align = "center" bgcolor = "#CCC0DA"|24/08/2009
|align = "center" bgcolor = "#CCC0DA"|<nowiki>-</nowiki>-
|-
|align = "center"|9
|align = "center" bgcolor = "#CCC0DA"|MiraLAX
|align = "center" bgcolor = "#CCC0DA"|Schering-Plough
|align = "center" bgcolor = "#CCC0DA"|6/10/2006
|align = "center" bgcolor = "#CCC0DA"|--
|align = "center" bgcolor = "#CCC0DA"|6/10/2009
|align = "center" bgcolor = "#CCC0DA"|<nowiki>-</nowiki>-
|-
|align = "center"|10
|align = "center" |alli
|align = "center" |GlaxoSmithKline
|align = "center" |7/2/2007
|align = "center" |6/1/2018
|align = "center" |7/2/2010
|align = "center" |6004996
|-
|align = "center"|11
|align = "center" |Zyrtec-D
|align = "center" |McNeil
|align = "center" |9/11/2007
|align = "center" |10/6/2022
|align = "center" |<nowiki>-</nowiki>-
|align = "center" |6469009, 6489329, 7014867, 7226614
|-
|align = "center"|12
|align = "center" |Zyrtec
|align = "center" |McNeil
|align = "center" |16/11/2007
|align = "center" |2/7/2018
|align = "center" |<nowiki>-</nowiki>-
|align = "center" |6455533
|-
|align = "center"|13
|align = "center" bgcolor = "#CCC0DA"|Prevacid 24 HR
|align = "center" bgcolor = "#CCC0DA"|Novartis
|align = "center" bgcolor = "#CCC0DA"|18/05/2009
|align = "center" bgcolor = "#CCC0DA"|--
|align = "center" bgcolor = "#CCC0DA"|18/05/2012
|align = "center" bgcolor = "#CCC0DA"|<nowiki>-</nowiki>-
|-
|align = "center"|14
|align = "center" bgcolor = "#CCC0DA"|Plan B One Step
|align = "center" bgcolor = "#CCC0DA"|Duramed
|align = "center" bgcolor = "#CCC0DA"|10/7/2009
|align = "center" bgcolor = "#CCC0DA"|--
|align = "center" bgcolor = "#CCC0DA"|10/7/2012
|align = "center" bgcolor = "#CCC0DA"|<nowiki>-</nowiki>-
|-
|align = "center"|15
|align = "center" |Zegerid OTC
|align = "center" |Schering-Plough
|align = "center" |1/12/2009
|align = "center" |15/07/2016
|align = "center" |<nowiki>-</nowiki>-
|align = "center" |6489346, 6645988, 6699885, 7399772
|-
|}

* Purple highlighted drugs are under FDA exclusivity period

===Trend Analysis===
#11 out of 22 recent drugs ('''50%''') which switched from Rx to OTC were '''patent protected'''
#4 out of 22 recent drugs ('''18.2%''') which switched from Rx to OTC were under '''FDA exclusivity period'''
#13 out of 22 recent drugs ('''59%''') were switched from Rx to OTC before their patent or FDA exclusivity expiry. 2 drugs switched after the expiry of patents
#6 out of these 13 drugs made a switch more than 10 years before expiry
#5 out of these 13 drugs made a switch between 3 to 10 years before expiry
 

===Potential Drugs for Rx-to-OTC Switch===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#8DB4E3"|'''S.No'''
|align = "center" bgcolor = "#8DB4E3"|'''Drug'''
|align = "center" bgcolor = "#8DB4E3"|'''Patent Expiry Date'''
|align = "center" bgcolor = "#8DB4E3"|'''Expected Switch Year'''
|align = "center" bgcolor = "#8DB4E3"|'''US Patent Numbers'''
|-
|align = "center"|1
|align = "center"|Allegra
|align = "center"|14/3/2017
|align = "center"|2012
|align = "center"|5578610, 6037353, 6187791, 6399632, 7138524
|-
|align = "center"|2
|align = "center"|Clarinex
|align = "center"|1/12/2018
|align = "center"|<nowiki>></nowiki>2013
|align = "center"| 6514520, 7211582, 7214683, 7214684
|-
|align = "center"|3
|align = "center"|Crestor
|align = "center"|17/6/2022
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|6858618, 6316460, 7030152, RE37314
|-
|align = "center"|4
|align = "center"|Lescol
|align = "center"|12/6/2012
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|5356896, 5354772,
|-
|align = "center"|5
|align = "center"|Lipitor
|align = "center"|8/1/2017
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|5969156, 4681893, 5273995, 5686104, 5969156, 6126971, RE40667
|-
|align = "center"|6
|align = "center"|Pravachol
|align = "center"|22/10/2014
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|5622985
|-
|align = "center"|7
|align = "center"|TriCor
|align = "center"|21/2/2023
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|7276249, 5145684, 6277405, 6375986 , 6652881, 7037529, 7041319, 7320802
|-
|align = "center"|8
|align = "center"|Vytorin
|align = "center"|25/4/2017
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|RE37721, 5846966,
|-
|align = "center"|9
|align = "center"|Zetia
|align = "center"|25/7/2022
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|7030106, 5846966, 7612058, RE37721
|-
|align = "center"|10
|align = "center"|AcipHex
|align = "center"|8/5/2013
|align = "center"|2013
|align = "center"|5045552
|-
|align = "center"|11
|align = "center"|Nexium
|align = "center"|25/11/2018
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|7411070, 5690960, 5714504, 5877192, 5900424, 6147103, 6166213, 6191148, 6369085, 6428810, 6875872
|-
|align = "center"|12
|align = "center"|Protonix
|align = "center"|30/3/2025
|align = "center"|2010
|align = "center"|7553498, 4758579, 7544370, 7550153
|-
|align = "center"|13
|align = "center"|Zofran
|align = "center"|7/12/2026
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|7544370, 4758579, 7550153, 7553498
|-
|align = "center"|14
|align = "center"|Propecia
|align = "center"|5/11/2013
|align = "center"|2011
|align = "center"|5571817, 5547957, 5886184
|-
|align = "center"|15
|align = "center"|Imitrex
|align = "center"|10/3/2014
|align = "center"|<nowiki>></nowiki>2010
|align = "center"|5554639, 5307953, 5705520
|-
|align = "center"|16
|align = "center"|Actonel
|align = "center"|10/12/2018
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|6165513, 5583122, 6096342
|-
|align = "center"|17
|align = "center"|Boniva
|align = "center"|2/9/2014
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|5662918, 4927814
|-
|align = "center"|18
|align = "center"|Fosamax
|align = "center"| 17/1/2019
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|6225294, 5462932, 5994329, 6015801
|-
|align = "center"|19
|align = "center"|Evista
|align = "center"|10/3/2017
|align = "center"|<nowiki>></nowiki>2014
|align = "center"| 6894064, 6797719, 6458811, 5393763, 5457117, 5478847, 5811120, 5972383, 6906086, RE38968, RE39049, RE39050
|-
|align = "center"|20
|align = "center"|Detrol
|align = "center"|11/5/2020
|align = "center"|<nowiki>></nowiki>2014
|align = "center"| 5382600, 6630162, 6770295, 6911217
|-
|align = "center"|21
|align = "center"|Ditropan
|align = "center"|22/11/2015
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|5674895, 5840754, 1 5912268, 6262115, 6919092
|-
|align = "center"|22
|align = "center"|Cialis
|align = "center"|26/4/2020
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|7182958, 5859006, 6140329, 6821975, 6943166
|-
|align = "center"|23
|align = "center"|Levitra
|align = "center"|31/10/2018
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|6362178, 7696206
|-
|align = "center"|24
|align = "center"|Viagra
|align = "center"|22/10/2019
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|6469012, 5250534
|-
|}
 
 
==US Market Survey - Physicians Preferences and Insights==
===Objectives of Survey===
* To find Physician preferences for OTC drugs in comparison to prescription drugs
* To find insights on OTC drugs market and usage
* To understand the effectiveness of different sources of marketing
===Research Methodology===
The research instrument used was a questionnaire survey administered to collect empirical data. The physician responses were kept confidential to encourage openness and disclosure. The respondents rated the questions on Yes or No, ticked the relevant choices from the options available and ranked the options on a numerical scale. All the responses were coded using a binary system logic and analysis was done to derive insights there after.
===Sample Size and Screening Criteria===
 
{|border="2" align = "center" cellspacing="0" cellpadding="4" width="35%"
|align = "center" bgcolor = "#8DB4E3"|'''Gender'''
|align = "center" bgcolor = "#8DB4E3"|'''Sample Size'''
|-
|align = "center"|Male
|align = "center"|18
|-
|align = "center"|Female
|align = "center"|2
|-
|align = "center" bgcolor = "#C5D9F1"|'''Total Physicians'''
|align = "center" bgcolor = "#C5D9F1"|'''20'''
|-
|}
 
{|border="2" align = "center" cellspacing="0" cellpadding="4" width="60%"
|align = "center" bgcolor = "#8DB4E3" colspan = "2"|'''Screening Criteria'''
|-
|align = "center"|Primary Medical Specialty
|align = "center"|General Physician/Family Practice
|-
|align = "center"|No. of years in practice
|align = "center"|10
|-
|align = "center"|No. of patients consulting per month
|align = "center"|150
|-
|}
 

===Survey Results===
*All the respondents would recommend an OTC drug for fever
*About 95% of the doctors feel that the usage of OTC drugs has increased in the past five years
*About 85% of them would do so for other minor ailments like cold/cough and acidity
[[Image:USFirst.png|center|thumb|800px]]
 
*Low cost, effective and easy availability are selected as the major factors that resulted in increased usage of OTC drugs
*All the respondents feel it is important to prescribe a drug that minimizes patients' out-of-pocket costs, while choosing between equally effective and safe medications
 
[[Image:US2.png|center|thumb|800px]]
*Advertisement is the major source of information on OTC drugs for most of the respondents
*Only 30% of respondents replied in positive when asked about permitting marketing executives to market OTC products through them
 
[[Image:US3.png|center|thumb|800px]]
*About 63% of the respondents reported the growth rate of OTC usage during 2005-2010 between 25% - 50% and equal percentage of respondents stated that patients are trusting OTC drugs more than they used to do before as the prime reason for the growth
{|align = "center"
|[[Image:US4.png|left|thumb|800px]][[Image:US5.png|right|thumb|800px]]
|-
|}
 
*Less than 50% of the patients are not prescribed OTC due to their medical history
[[Image:non pres due to medical history.jpg|center|thumb|800px]]
 
*The case of patients coming to the doctor due to side effects from OTC drugs happens once a month
*About 45% of the respondents feel that non-prescription of drugs is not a serious problem
{| align="center"
|[[Image:Seriousness of non-prescription1.jpg|left|thumb|488×299px]][[Image:side effects1.jpg|right|thumb|488×304px]]
|-
|}

 
*85% of the doctors feel that the information on the label of OTC drugs is sufficient for the patients, in order to take OTC medicines
*50% of the doctors feel that more OTC drugs should be included under Medicare/insurance coverage
 
 
'''The effective ranking of the ailments in the order of safety of available OTC drugs is as follows:'''
[[Image:effective ranking.jpg|center|thumb|800px]]
[[Media:Working of Effective Ranking & Scoring.xls| To see the calculation of the effective scores and effective ranking, click on this link]]

==Indian Market Survey - Physicians Preferences and Insights==
===Objectives of the Survey===

The reason for carrying out this research is to determine the scope of potential switch of prescription drugs to over the counter drugs in the Indian pharma industry. The study is particularly focused at the scope of making statins, a drug for reducing cholesterol level, available over-the-counter. The study aims to understand how successful a switch would be, and if it is safe for such drugs to be made available without prescription. The study also aims at determining the marketing pattern of over the counter drugs, and how it can be improved in future.

The objectives for the survey are :

* To understand the effectiveness of OTC drug marketing campaigns in India
* To understand the source of information for the OTC drugs among doctors
* To explore the potential of switch from Rx to OTC drugs
* To gauge the current prescription pattern of statins in India
* To identify if statins can be switched to OTC

===Research Methodology===
The research instrument used was a questionnaire survey administered to collect empirical data. The physician responses were kept confidential to encourage openness and disclosure. The respondents rated the questions on Yes or No, ticked the relevant choices from the options available and ranked the options on a numerical scale. All the responses were coded using a binary system logic and analysis was done to derive insights there after.

===Sample Size and Screening Criteria===
'''Screening Criteria'''
{|border="2" align = "center" cellspacing="0" cellpadding="4" width="60%"
|align = "center" bgcolor = "#8DB4E3" colspan = "2"|'''Screening Criteria'''
|-
|align = "center"|Medical Specialty
|align = "center"|General Physician, Consulting Physician, Gynaecologist, Dermatologist, Cardiologist, Pediatrician
|-
|align = "center"|No. of years in practice
|align = "center"|10
|-
|align = "center"|No. of patients consulting per month
|align = "center"|150
|-
|}

 

'''Sample Size'''
{|border="2" align = "center" cellspacing="0" cellpadding="4" width="25%" align = "center"
|align = "center" bgcolor = "#8DB4E3"|'''Gender'''
|align = "center" bgcolor = "#8DB4E3"|'''Sample Size'''
|-
|align = "center"|Male
|align = "center"|44
|-
|align = "center"|Female
|align = "center"|16
|-
|align = "center" bgcolor = "#C5D9F1"|'''Total Physicians'''
|align = "center" bgcolor = "#C5D9F1"|'''60'''
|-
|}
 

{|border="2" cellspacing="0" cellpadding="4" width="25%" align = "center"
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Medical Specialty-wise Breakup'''
|-
|General Physician
|align = "center"|17
|-
|Consulting Physician
|align = "center"|9
|-
|Gynecologist
|align = "center"|9
|-
|Dermatologist
|align = "center"|4
|-
|Cardiologist
|align = "center"|12
|-
|Pediatrician
|align = "center"|6
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Geographywise Breakup'''
|-
|Mumbai
|align = "center"|15
|-
|Hyderabad
|align = "center"|15
|-
|Delhi NCR
|align = "center"|14
|-
|Bangalore
|align = "center"|16
|-
|}
 

===Survey Results===
* 97% of the Indian doctors feel that the usage of OTC drugs has increased in the past 5 years
* Indian doctors feel that the usage of OTC drugs has increased by more than 50% in the past 5 years
* Ease in the availability of OTC drugs, Advertisements and Saving time are the major reasons for increase in the usage of OTC drugs
{|align = "center" width="100%"
|[[Image:Opinion on increased usage - India1.jpg|left|thumb|520px]][[Image:Reasons for increase in OTC Usage - India.jpg|right|thumb|520px]]
|-
|}
 
* Headache, Cold/Cough and acidity are the most common ailments for which physicians prefer giving an OTC drug
[[Image:Physician preferences for minor ailments - india.jpg|center|thumb|603px]]
 
* More than 80% of the patients are not prescribed OTC drugs beacuse of their prior medical history
[[Image:non pres due to medical history - india.jpg|center|thumb|619px]]
 
* Only 13% of the doctors feel that the information on the labels of OTC drugs is sufficient
* 98% of the doctors feel that drug-drug interactions might be a potential danger for OTC drugs
* 48% of the patients come once a month to doctor due to side effects caused by OTC drugs
[[Image:Patients coming due to side effects - India.jpg|center|thumb|554px]]
 
* 95% of the doctors feel that the problem of taking OTCs in India is serious
[[Image:Seriousness of taking otc - india.jpg|center|thumb|547px]]
 

'''The effective ranking of the ailments in the order of safety of available OTC drugs is as follows:'''
[[Image:effective ranking - india.jpg|center|thumb|800px]]
[[Media:Working of Effective Ranking & Scoring - India.xls| To see the calculation of the effective scores and effective ranking, click on this link]]
 

* 72% of the doctors see an opportunity for Rx-to-OTC switch in Indian pharma market
* Drugs relating to Vitamins, Antacids, Cuts, wounds and burns & Cold/Cough have a better potential to do well as an OTC drug
[[Image:category with better potential for switch - india.jpg|center|thumb|570px]]
 

'''Effectiveness of marketing campaigns'''
* Advertisements are a major source of information for Indians on OTC drugs
[[Image:Source of info - india.jpg|center|thumb|514px]]
 

* Only 23% of the doctors permit marketing executives to market OTC products through them
* Quality is the most important factor affecting the choice of a drug
[[Image:factor affecting choice of a drug - india.jpg|center|thumb|484px]]
 

'''Results on Statins'''
* More than 50% of the patients with high cholesteral level fall in the age group of 40-60 years
* 73% of the patients with high cholesteral level are prescribed Statin by doctors
{|align = "center" width = "90%"
|[[Image:age grp increased cholesterol - india1.jpg|left|thumb|485px]][[Image:drug prescribed for cholesterol - india1.jpg|right|thumb|485px]]
|-
|}
 
* Atrovastatin and Rosuvastatin are prescribed more than 90% of the times (whenever statins are prescribed) by doctors to patients with high cholesterol level
[[Image:prescribed statin - india.jpg|center|thumb|526px]]
 
* Sale and effectiveness of the drug, Manufacturer of the drug and Patient type are the major factors for choosing any type/brand of statin
[[Image:factors for choosing statin - india.jpg|center|thumb|565px]]
 
* Only 25% of the doctors feel that statins safe to be made available as OTC drugs for low- to-moderate risk group

Rx to OTC Switch-Market Analysis

2011-09-15T12:28:43Z

Abhay.goel: /* Sample Size and Screening Criteria */

==Introduction==

Over-the-counter (OTC) drugs are medicines that may be sold directly to a consumer without a prescription from a healthcare professional, and are commonly used to treat symptoms of common illnesses that may not require the direct supervision of a physician. 
*For a medicine to be granted OTC status, it must have a wide safety margin and be effective, and must bear understandable labeling to ensure proper use
*More than 700 OTC products on the market today use ingredients or dosages, that were available only by prescription, less than 30 years ago
*Rx to OTC switch refers to the transfer of proven prescription drugs (Rx) to non-prescription, over-the-counter (OTC) status. Rx to OTC switch is a data-driven, scientifically rigorous, and highly regulated process that allows consumers to have OTC access to a growing range of medicines
 
There are two ways in which drugs are commonly switched as approved by FDA in US :

#The OTC Drug Review
#*Began in 1972
#*Ongoing assessment of the safety and effectiveness of all nonprescription drugs
#*Panels of non-government experts review active ingredients in marketed OTC drug products to determine whether they can be classified as safe and effective
#*About 40 former prescription-only drug ingredients have been switched by this process
#New drug application (NDA) process
#*Manufacturers submit data to the FDA showing the drug is appropriate for self-administration.
#*The submission includes studies showing that the product's labeling can be read, understood, and followed by the consumer without the guidance of a health care provider
#*Some drugs are approved initially as OTC drugs, but most are first approved for prescription use and later switched to OTC

==Market Overview==
===OTC Market===
[[Image:OTC Market.png|center|thumb|900px|Source:Kalorama Information]]
{|border="2" align="center" cellspacing="0" cellpadding="4" width="28%"
|align = "center" bgcolor = "#8DB4E3"|'''Time Period'''
|align = "center" bgcolor = "#8DB4E3"|'''CAGR'''
|-
|align = "center"|2005-2009
|align = "center"|3.3%
|-
|align = "center"|2009-2014
|align = "center"|2.7%
|-
|align = "center"|2005-2014
|align = "center"|3.0%
|-
|}
 

===Rx vs. OTC Market===
'''Total Pharmaceutical Market by Country, 2009 ($B)'''
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#8DB4E3"|'''Country'''
|align = "center" bgcolor = "#8DB4E3"|'''Rx Market'''
|align = "center" bgcolor = "#8DB4E3"|'''OTC Market'''
|align = "center" bgcolor = "#8DB4E3"|'''Total Pharma Market'''
|align = "center" bgcolor = "#8DB4E3"|'''OTC as % of Total Pharma Market'''
|-
|align = "center" bgcolor = "#DBE5F1"|'''United States'''
|align = "center" bgcolor = "#DBE5F1"|214
|align = "center" bgcolor = "#DBE5F1"|18
|align = "center" bgcolor = "#DBE5F1"|232
|align = "center" bgcolor = "#DBE5F1"|'''7.8'''
|-
|align = "center"|'''Japan'''
|align = "center"|56
|align = "center"|11
|align = "center"|67
|align = "center"|'''16.4'''
|-
|align = "center"|'''Germany'''
|align = "center"|35
|align = "center"|5
|align = "center"|40
|align = "center"|'''12.5'''
|-
|align = "center"|'''France'''
|align = "center"|32
|align = "center"|4
|align = "center"|36
|align = "center"|'''11.1'''
|-
|align = "center"|'''China'''
|align = "center"|16
|align = "center"|5
|align = "center"|21
|align = "center"|'''23.1'''
|-
|align = "center"|'''United Kingdom'''
|align = "center"|17
|align = "center"|3
|align = "center"|20
|align = "center"|'''15.0'''
|-
|align = "center"|'''Russia'''
|align = "center"|13
|align = "center"|3
|align = "center"|16
|align = "center"|'''18.8'''
|-
|align = "center"|'''Brazil'''
|align = "center"|10
|align = "center"|2
|align = "center"|12
|align = "center"|'''16.7'''
|-
|align = "center"|'''Mexico'''
|align = "center"|9
|align = "center"|2
|align = "center"|11
|align = "center"|'''18.1'''
|-
|align = "center"|'''India'''
|align = "center"|6
|align = "center"|3
|align = "center"|9
|align = "center"|'''33.3'''
|-
|}
Source: Kalorama Information

===Rx to OTC Switches===
{|align="center"
|[[Image:Rx to OTC Switches market1.png|left|thumb|800px|Source:Kalorama Information]][[Image:Market Segmentation (2008).png|right|thumb|800px|Source:Kalorama Information]]
|-
|}
*CAGR for 2008-2013 is '''9.4%'''

===Major OTC Players===
[[Image:OTC Players1.png|center|thumb|800px|Source:Company Websites]]
 

===Sales Data for selected Rx to OTC Switches, USA===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#8DB4E3"|'''S.No'''
|align = "center" bgcolor = "#8DB4E3"|'''Switched Drug'''
|align = "center" bgcolor = "#8DB4E3"|'''Manufacturer/Marketer'''
|align = "center" bgcolor = "#8DB4E3"|'''Drug Category'''
|align = "center" bgcolor = "#8DB4E3"|'''Switch Year'''
|align = "center" bgcolor = "#8DB4E3"|'''First 12-Month Sales (in $M)'''
|-
|align = "center"|1
|align = "center"|Alli
|align = "center"|Glaxo SmithKline Consumer Healthcare
|align = "center"|Weight Loss Aid
|align = "center"|2007
|align = "center" bgcolor = "#DBE5F1"|80
|-
|align = "center"|2
|align = "center"|MiraLax
|align = "center"|Schering-Plough Healthcare
|align = "center"|Gastrointestinal
|align = "center"|2006
|align = "center" bgcolor = "#DBE5F1"|40
|-
|align = "center"|3
|align = "center"|Prilosec OTC
|align = "center"|Procter & Gamble
|align = "center"|Gastrointestinal
|align = "center"|2003
|align = "center" bgcolor = "#DBE5F1"|130
|-
|align = "center"|4
|align = "center"|Claritin
|align = "center"|Schering-Plough Healthcare
|align = "center"|Allergy
|align = "center"|2002
|align = "center" bgcolor = "#DBE5F1"|380
|-
|align = "center"|5
|align = "center"|Nicoderm CQ
|align = "center"|Glaxo SmithKline Consumer Healthcare
|align = "center"|Smoking Cessation
|align = "center"|1996
|align = "center" bgcolor = "#DBE5F1"|160
|-
|align = "center"|6
|align = "center"|Nicorette
|align = "center"|Glaxo SmithKline Consumer Healthcare
|align = "center"|Smoking Cessation
|align = "center"|1996
|align = "center" bgcolor = "#DBE5F1"|195
|-
|align = "center"|7
|align = "center"|Rogaine
|align = "center"|McNeil Consumer Healthcare
|align = "center"|Hair Loss
|align = "center"|1996
|align = "center" bgcolor = "#DBE5F1"|180
|-
|align = "center"|8
|align = "center"|Pepcid AC
|align = "center"|Johnson & Johnson- Merck Consumer Pharmaceuticals Co.
|align = "center"|Gastrointestinal
|align = "center"|1995
|align = "center" bgcolor = "#DBE5F1"|200
|-
|align = "center"|9
|align = "center"|Zantac 75
|align = "center"|Boehringer Ingelheim Consumer Healthcare Products
|align = "center"|Gastrointestinal
|align = "center"|1995
|align = "center" bgcolor = "#DBE5F1"|140
|-
|align = "center"|10
|align = "center"|Aleve
|align = "center"|Bayer Consumer Care
|align = "center"|Analgesic
|align = "center"|1994
|align = "center" bgcolor = "#DBE5F1"|110
|-
|}
Source:Company Websites, Press Releases and Journals

===Factors Affecting Rx to OTC Switch===
[[Image:Factors.png|center|thumb|800px]]

==Trends in Rx to OTC Switches==
===Rx-to-OTC Switches Since 2000===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#8DB4E3"|'''S.No'''
|align = "center" bgcolor = "#8DB4E3"|'''Ingredient'''
|align = "center" bgcolor = "#8DB4E3"|'''Product Category'''
|align = "center" bgcolor = "#8DB4E3"|'''Date of OTC Approval'''
|align = "center" bgcolor = "#8DB4E3"|'''Product Examples'''
|align = "center" bgcolor = "#8DB4E3"|'''Company'''
|-
|align = "center"|1
|align = "center"|ibuprofen (NDA)
|align = "center"|migraine
|align = "center"|25/02/2000
|align = "center"|Motrin Migraine Pain
|align = "center"|McNeil Consumer Healthcare
|-
|align = "center"|2
|align = "center" bgcolor = "#B8CCE4"|docosanol (NDA)
|align = "center" bgcolor = "#B8CCE4"|cold sore/fever blister
|align = "center" bgcolor = "#B8CCE4"|25/07/2000
|align = "center" bgcolor = "#B8CCE4"|Abreva Cream
|align = "center" bgcolor = "#B8CCE4"|Avanir Pharmaceuticals
|-
|align = "center" rowspan = "2"|3
|align = "center" bgcolor = "#B8CCE4"|famotidine, calcium carbonate,
|align = "center" bgcolor = "#B8CCE4"|heartburn,
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|17/10/2000
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|Pepcid Complete
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|J&J/Merck
|-
|align = "center" bgcolor = "#B8CCE4"|magnesium hydroxide (NDA)
|align = "center" bgcolor = "#B8CCE4"|acid indigestion
|-
|align = "center"|4
|align = "center"|butenafine hydrochloride (NDA)
|align = "center"|athlete's foot, jock itch, ringworm
|align = "center"|7/12/2001
|align = "center"|Lotrimin Ultra
|align = "center"|Schering-Plough
|-
|align = "center" rowspan = "2"|5
|align = "center"|ibuprofen, pseudoephedrine HCl,
|align = "center" rowspan = "2"|analgesic/decongestant
|align = "center" rowspan = "2"|18/04/2002
|align = "center" rowspan = "2"|Children’s Advil Cold
|align = "center" rowspan = "2"|Wyeth
|-
|align = "center"|suspension for pediatric use (NDA)
|-
|align = "center"|6
|align = "center" bgcolor = "#B8CCE4"|guaifenesin extended-release tablet (NDA)
|align = "center" bgcolor = "#B8CCE4"|expectorant
|align = "center" bgcolor = "#B8CCE4"|12/7/2002
|align = "center" bgcolor = "#B8CCE4"|Mucinex
|align = "center" bgcolor = "#B8CCE4"|Adams Respiratory Therapeutics
|-
|align = "center"|7
|align = "center" bgcolor = "#B8CCE4"|nicotine polacrilex troche/lozenge (NDA)
|align = "center" bgcolor = "#B8CCE4"|smoking cessation
|align = "center" bgcolor = "#B8CCE4"|31/10/2002
|align = "center" bgcolor = "#B8CCE4"|Commit
|align = "center" bgcolor = "#B8CCE4"|GlaxoSmithKline
|-
|align = "center"|8
|align = "center"|loratadine (NDA)
|align = "center"|antihistamine
|align = "center"|27/11/2002
|align = "center"|Claritin Tablets, Claritin RediTabs, Claritin Syrup
|align = "center"|Schering-Plough
|-
|align = "center" rowspan = "2"|9
|align = "center" rowspan = "2"|loratadine, pseudoephededrine sulfate (NDA)
|align = "center"|antihistamine/
|align = "center" rowspan = "2"|27/11/2002
|align = "center" rowspan = "2"|Claritin-D 12 Hour Extended Release Tablets,
|align = "center" rowspan = "2"|Schering-Plough
|-
|align = "center"|decongestant
|-
|align = "center"|10
|align = "center" bgcolor = "#B8CCE4"|omeprazole magnesium
|align = "center" bgcolor = "#B8CCE4"|acid reducer to treat frequent heartburn
|align = "center" bgcolor = "#B8CCE4"|20/06/2003
|align = "center" bgcolor = "#B8CCE4"|Prilosec OTC
|align = "center" bgcolor = "#B8CCE4"|Procter & Gamble
|-
|align = "center" rowspan = "2"|11
|align = "center" bgcolor = "#B8CCE4"|loratadine (NDA)
|align = "center" bgcolor = "#B8CCE4"|hives relief
|align = "center" bgcolor = "#B8CCE4"|15/11/2003
|align = "center" bgcolor = "#B8CCE4"|Claritin hives relief
|align = "center" bgcolor = "#B8CCE4"|Schering-Plough
|-
|align = "center"|diphenhydramine citrate & ibuprofen (NDA); diphenhydramine HCl & ibuprofen potassium (NDA)
|align = "center"|analgesic sleep-aid
|align = "center"|21/12/2005
|align = "center"|Advil PM
|align = "center"|Wyeth
|-
|align = "center"|12
|align = "center" bgcolor = "#B8CCE4"|ecamsule (combined with avobenzone and octocrylene (NDA)
|align = "center" bgcolor = "#B8CCE4"|sunscreen
|align = "center" bgcolor = "#B8CCE4"|21/07/2006
|align = "center" bgcolor = "#B8CCE4"|Anthelios SX
|align = "center" bgcolor = "#B8CCE4"|L’Oreal
|-
|align = "center" rowspan = "2"|13
|align = "center" bgcolor = "#CCC0DA"|levonorgestrel (NDA)
|align = "center" bgcolor = "#CCC0DA"|contraceptive
|align = "center" bgcolor = "#CCC0DA"|24/08/2006
|align = "center" bgcolor = "#CCC0DA"|Plan B
|align = "center" bgcolor = "#CCC0DA"|Duramed
|-
|align = "center" bgcolor = "#CCC0DA"|polyethylene glycol 3350 (NDA)
|align = "center" bgcolor = "#CCC0DA"|laxative
|align = "center" bgcolor = "#CCC0DA"|6/10/2006
|align = "center" bgcolor = "#CCC0DA"|MiraLAX
|align = "center" bgcolor = "#CCC0DA"|Schering-Plough
|-
|align = "center"|14
|align = "center"|ketotifen (NDA)
|align = "center"|antihistamine eye drops
|align = "center"|19/10/2006
|align = "center"|Zaditor
|align = "center"|Novartis
|-
|align = "center" rowspan = "2"|15
|align = "center" bgcolor = "#B8CCE4"|orlistat (NDA)
|align = "center" bgcolor = "#B8CCE4"|weight loss aid
|align = "center" bgcolor = "#B8CCE4"|7/2/2007
|align = "center" bgcolor = "#B8CCE4"|alli
|align = "center" bgcolor = "#B8CCE4"|GlaxoSmithKline
|-
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|cetirizine HCl & pseudoephedrine HCl (NDA)
|align = "center" bgcolor = "#B8CCE4"|antihistamine/
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|9/11/2007
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|Zyrtec-D
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|McNeil
|-
|align = "center"|16
|align = "center" bgcolor = "#B8CCE4"|decongestant
|-
|align = "center" rowspan = "2"|17
|align = "center" bgcolor = "#B8CCE4"|cetirizine HCl (NDA)
|align = "center" bgcolor = "#B8CCE4"|antihistamine, hives relief
|align = "center" bgcolor = "#B8CCE4"|16/11/2007
|align = "center" bgcolor = "#B8CCE4"|Zyrtec
|align = "center" bgcolor = "#B8CCE4"|McNeil
|-
|align = "center" bgcolor = "#CCC0DA" rowspan = "2"|lansoprazole (NDA)
|align = "center" bgcolor = "#CCC0DA"|acid reducer to treat
|align = "center" bgcolor = "#CCC0DA" rowspan = "2"|18/05/2009
|align = "center" bgcolor = "#CCC0DA" rowspan = "2"|Prevacid 24 HR
|align = "center" bgcolor = "#CCC0DA" rowspan = "2"|Novartis
|-
|align = "center"|18
|align = "center" bgcolor = "#CCC0DA"|frequent heartburn
|-
|align = "center" rowspan = "2"|19
|align = "center" bgcolor = "#CCC0DA"|levonorgestrel (NDA)
|align = "center" bgcolor = "#CCC0DA"|contraceptive
|align = "center" bgcolor = "#CCC0DA"|10/7/2009
|align = "center" bgcolor = "#CCC0DA"|Plan B One Step
|align = "center" bgcolor = "#CCC0DA"|Duramed
|-
|align = "center" bgcolor = "#B8CCE4"|omeprazole and sodium
|align = "center" bgcolor = "#B8CCE4"|acid reducer to treat
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|1/12/2009
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|Zegerid OTC
|align = "center" bgcolor = "#B8CCE4" rowspan = "2"|Schering-Plough
|-
|align = "center"|20
|align = "center" bgcolor = "#B8CCE4"|bicarbonate (NDA)
|align = "center" bgcolor = "#B8CCE4"|frequent heartburn
|-
|}

* Blue highlighted drugs are patent-protected 
* Purple highlighted drugs are under FDA exclusivity period

===Rx to OTC Switches before patent expiry===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#8DB4E3"|'''S.No'''
|align = "center" bgcolor = "#8DB4E3"|'''Product Examples'''
|align = "center" bgcolor = "#8DB4E3"|'''Company'''
|align = "center" bgcolor = "#8DB4E3"|'''Date of OTC Approval'''
|align = "center" bgcolor = "#8DB4E3"|'''Patent Expiry'''
|align = "center" bgcolor = "#8DB4E3"|'''FDA Exclusivity'''
|align = "center" bgcolor = "#8DB4E3"|'''Patent Number'''
|-
|align = "center"|1
|align = "center" |Abreva Cream
|align = "center" |Avanir Pharmaceuticals
|align = "center" |25/07/2000
|align = "center" |28/04/2014
|align = "center" |--
|align = "center" |4874794
|-
|align = "center"|2
|align = "center" |Pepcid Complete
|align = "center" |J&J/Merck
|align = "center" |17/10/2000
|align = "center" |15/10/2000
|align = "center" |--
|align = "center" |4283408
|-
|align = "center"|3
|align = "center" |Mucinex
|align = "center" |Adams Respiratory Therapeutics
|align = "center" |12/7/2002
|align = "center" |28/04/2020
|align = "center" |--
|align = "center" |6372252
|-
|align = "center"|4
|align = "center" |Commit
|align = "center" |GlaxoSmithKline
|align = "center" |31/10/2002
|align = "center" |21/08/2010
|align = "center" |--
|align = "center" |5110605
|-
|align = "center"|5
|align = "center" |Prilosec OTC
|align = "center" |Procter & Gamble
|align = "center" |20/06/2003
|align = "center" |15/11/2019
|align = "center" |--
|align = "center" |5690960, 5753265, 5817338, 5900424, 6403616, 6428810
|-
|align = "center"|6
|align = "center" |Claritin hives relief
|align = "center" |Schering-Plough
|align = "center" |15/11/2003
|align = "center" |19/06/2002
|align = "center" |--
|align = "center" |4282233
|-
|align = "center"|7
|align = "center" |Anthelios SX
|align = "center" |L’Oreal
|align = "center" |21/07/2006
|align = "center" |24/12/2013
|align = "center" |--
|align = "center" |5587150
|-
|align = "center"|8
|align = "center" bgcolor = "#CCC0DA"|Plan B
|align = "center" bgcolor = "#CCC0DA"|Duramed
|align = "center" bgcolor = "#CCC0DA"|24/08/2006
|align = "center" bgcolor = "#CCC0DA"|--
|align = "center" bgcolor = "#CCC0DA"|24/08/2009
|align = "center" bgcolor = "#CCC0DA"|<nowiki>-</nowiki>-
|-
|align = "center"|9
|align = "center" bgcolor = "#CCC0DA"|MiraLAX
|align = "center" bgcolor = "#CCC0DA"|Schering-Plough
|align = "center" bgcolor = "#CCC0DA"|6/10/2006
|align = "center" bgcolor = "#CCC0DA"|--
|align = "center" bgcolor = "#CCC0DA"|6/10/2009
|align = "center" bgcolor = "#CCC0DA"|<nowiki>-</nowiki>-
|-
|align = "center"|10
|align = "center" |alli
|align = "center" |GlaxoSmithKline
|align = "center" |7/2/2007
|align = "center" |6/1/2018
|align = "center" |7/2/2010
|align = "center" |6004996
|-
|align = "center"|11
|align = "center" |Zyrtec-D
|align = "center" |McNeil
|align = "center" |9/11/2007
|align = "center" |10/6/2022
|align = "center" |<nowiki>-</nowiki>-
|align = "center" |6469009, 6489329, 7014867, 7226614
|-
|align = "center"|12
|align = "center" |Zyrtec
|align = "center" |McNeil
|align = "center" |16/11/2007
|align = "center" |2/7/2018
|align = "center" |<nowiki>-</nowiki>-
|align = "center" |6455533
|-
|align = "center"|13
|align = "center" bgcolor = "#CCC0DA"|Prevacid 24 HR
|align = "center" bgcolor = "#CCC0DA"|Novartis
|align = "center" bgcolor = "#CCC0DA"|18/05/2009
|align = "center" bgcolor = "#CCC0DA"|--
|align = "center" bgcolor = "#CCC0DA"|18/05/2012
|align = "center" bgcolor = "#CCC0DA"|<nowiki>-</nowiki>-
|-
|align = "center"|14
|align = "center" bgcolor = "#CCC0DA"|Plan B One Step
|align = "center" bgcolor = "#CCC0DA"|Duramed
|align = "center" bgcolor = "#CCC0DA"|10/7/2009
|align = "center" bgcolor = "#CCC0DA"|--
|align = "center" bgcolor = "#CCC0DA"|10/7/2012
|align = "center" bgcolor = "#CCC0DA"|<nowiki>-</nowiki>-
|-
|align = "center"|15
|align = "center" |Zegerid OTC
|align = "center" |Schering-Plough
|align = "center" |1/12/2009
|align = "center" |15/07/2016
|align = "center" |<nowiki>-</nowiki>-
|align = "center" |6489346, 6645988, 6699885, 7399772
|-
|}

* Purple highlighted drugs are under FDA exclusivity period

===Trend Analysis===
#11 out of 22 recent drugs ('''50%''') which switched from Rx to OTC were '''patent protected'''
#4 out of 22 recent drugs ('''18.2%''') which switched from Rx to OTC were under '''FDA exclusivity period'''
#13 out of 22 recent drugs ('''59%''') were switched from Rx to OTC before their patent or FDA exclusivity expiry. 2 drugs switched after the expiry of patents
#6 out of these 13 drugs made a switch more than 10 years before expiry
#5 out of these 13 drugs made a switch between 3 to 10 years before expiry
 

===Potential Drugs for Rx-to-OTC Switch===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#8DB4E3"|'''S.No'''
|align = "center" bgcolor = "#8DB4E3"|'''Drug'''
|align = "center" bgcolor = "#8DB4E3"|'''Patent Expiry Date'''
|align = "center" bgcolor = "#8DB4E3"|'''Expected Switch Year'''
|align = "center" bgcolor = "#8DB4E3"|'''US Patent Numbers'''
|-
|align = "center"|1
|align = "center"|Allegra
|align = "center"|14/3/2017
|align = "center"|2012
|align = "center"|5578610, 6037353, 6187791, 6399632, 7138524
|-
|align = "center"|2
|align = "center"|Clarinex
|align = "center"|1/12/2018
|align = "center"|<nowiki>></nowiki>2013
|align = "center"| 6514520, 7211582, 7214683, 7214684
|-
|align = "center"|3
|align = "center"|Crestor
|align = "center"|17/6/2022
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|6858618, 6316460, 7030152, RE37314
|-
|align = "center"|4
|align = "center"|Lescol
|align = "center"|12/6/2012
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|5356896, 5354772,
|-
|align = "center"|5
|align = "center"|Lipitor
|align = "center"|8/1/2017
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|5969156, 4681893, 5273995, 5686104, 5969156, 6126971, RE40667
|-
|align = "center"|6
|align = "center"|Pravachol
|align = "center"|22/10/2014
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|5622985
|-
|align = "center"|7
|align = "center"|TriCor
|align = "center"|21/2/2023
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|7276249, 5145684, 6277405, 6375986 , 6652881, 7037529, 7041319, 7320802
|-
|align = "center"|8
|align = "center"|Vytorin
|align = "center"|25/4/2017
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|RE37721, 5846966,
|-
|align = "center"|9
|align = "center"|Zetia
|align = "center"|25/7/2022
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|7030106, 5846966, 7612058, RE37721
|-
|align = "center"|10
|align = "center"|AcipHex
|align = "center"|8/5/2013
|align = "center"|2013
|align = "center"|5045552
|-
|align = "center"|11
|align = "center"|Nexium
|align = "center"|25/11/2018
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|7411070, 5690960, 5714504, 5877192, 5900424, 6147103, 6166213, 6191148, 6369085, 6428810, 6875872
|-
|align = "center"|12
|align = "center"|Protonix
|align = "center"|30/3/2025
|align = "center"|2010
|align = "center"|7553498, 4758579, 7544370, 7550153
|-
|align = "center"|13
|align = "center"|Zofran
|align = "center"|7/12/2026
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|7544370, 4758579, 7550153, 7553498
|-
|align = "center"|14
|align = "center"|Propecia
|align = "center"|5/11/2013
|align = "center"|2011
|align = "center"|5571817, 5547957, 5886184
|-
|align = "center"|15
|align = "center"|Imitrex
|align = "center"|10/3/2014
|align = "center"|<nowiki>></nowiki>2010
|align = "center"|5554639, 5307953, 5705520
|-
|align = "center"|16
|align = "center"|Actonel
|align = "center"|10/12/2018
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|6165513, 5583122, 6096342
|-
|align = "center"|17
|align = "center"|Boniva
|align = "center"|2/9/2014
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|5662918, 4927814
|-
|align = "center"|18
|align = "center"|Fosamax
|align = "center"| 17/1/2019
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|6225294, 5462932, 5994329, 6015801
|-
|align = "center"|19
|align = "center"|Evista
|align = "center"|10/3/2017
|align = "center"|<nowiki>></nowiki>2014
|align = "center"| 6894064, 6797719, 6458811, 5393763, 5457117, 5478847, 5811120, 5972383, 6906086, RE38968, RE39049, RE39050
|-
|align = "center"|20
|align = "center"|Detrol
|align = "center"|11/5/2020
|align = "center"|<nowiki>></nowiki>2014
|align = "center"| 5382600, 6630162, 6770295, 6911217
|-
|align = "center"|21
|align = "center"|Ditropan
|align = "center"|22/11/2015
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|5674895, 5840754, 1 5912268, 6262115, 6919092
|-
|align = "center"|22
|align = "center"|Cialis
|align = "center"|26/4/2020
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|7182958, 5859006, 6140329, 6821975, 6943166
|-
|align = "center"|23
|align = "center"|Levitra
|align = "center"|31/10/2018
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|6362178, 7696206
|-
|align = "center"|24
|align = "center"|Viagra
|align = "center"|22/10/2019
|align = "center"|<nowiki>></nowiki>2014
|align = "center"|6469012, 5250534
|-
|}
 
 
==US Market Survey - Physicians Preferences and Insights==
===Objectives of Survey===
* To find Physician preferences for OTC drugs in comparison to prescription drugs
* To find insights on OTC drugs market and usage
* To understand the effectiveness of different sources of marketing
===Research Methodology===
The research instrument used was a questionnaire survey administered to collect empirical data. The physician responses were kept confidential to encourage openness and disclosure. The respondents rated the questions on Yes or No, ticked the relevant choices from the options available and ranked the options on a numerical scale. All the responses were coded using a binary system logic and analysis was done to derive insights there after.
===Sample Size and Screening Criteria===
 
{|border="2" align = "center" cellspacing="0" cellpadding="4" width="35%"
|align = "center" bgcolor = "#8DB4E3"|'''Gender'''
|align = "center" bgcolor = "#8DB4E3"|'''Sample Size'''
|-
|align = "center"|Male
|align = "center"|18
|-
|align = "center"|Female
|align = "center"|2
|-
|align = "center" bgcolor = "#C5D9F1"|'''Total Physicians'''
|align = "center" bgcolor = "#C5D9F1"|'''20'''
|-
|}
 
{|border="2" align = "center" cellspacing="0" cellpadding="4" width="60%"
|align = "center" bgcolor = "#8DB4E3" colspan = "2"|'''Screening Criteria'''
|-
|align = "center"|Primary Medical Specialty
|align = "center"|General Physician/Family Practice
|-
|align = "center"|No. of years in practice
|align = "center"|10
|-
|align = "center"|No. of patients consulting per month
|align = "center"|150
|-
|}
 

===Survey Results===
*All the respondents would recommend an OTC drug for fever
*About 95% of the doctors feel that the usage of OTC drugs has increased in the past five years
*About 85% of them would do so for other minor ailments like cold/cough and acidity
[[Image:USFirst.png|center|thumb|800px]]
 
*Low cost, effective and easy availability are selected as the major factors that resulted in increased usage of OTC drugs
*All the respondents feel it is important to prescribe a drug that minimizes patients' out-of-pocket costs, while choosing between equally effective and safe medications
 
[[Image:US2.png|center|thumb|800px]]
*Advertisement is the major source of information on OTC drugs for most of the respondents
*Only 30% of respondents replied in positive when asked about permitting marketing executives to market OTC products through them
 
[[Image:US3.png|center|thumb|800px]]
*About 63% of the respondents reported the growth rate of OTC usage during 2005-2010 between 25% - 50% and equal percentage of respondents stated that patients are trusting OTC drugs more than they used to do before as the prime reason for the growth
{|align = "center"
|[[Image:US4.png|left|thumb|800px]][[Image:US5.png|right|thumb|800px]]
|-
|}
 
*Less than 50% of the patients are not prescribed OTC due to their medical history
[[Image:non pres due to medical history.jpg|center|thumb|800px]]
 
*The case of patients coming to the doctor due to side effects from OTC drugs happens once a month
*About 90% of the respondents feel that non-prescription of drugs is not a serious problem
{| align="center"
|[[Image:Seriousness of non-prescription1.jpg|left|thumb|488×299px]][[Image:side effects1.jpg|right|thumb|488×304px]]
|-
|}

 
*85% of the doctors feel that the information on the label of OTC drugs is sufficient for the patients, in order to take OTC medicines
*50% of the doctors feel that more OTC drugs should be included under Medicare/insurance coverage
 
 
'''The effective ranking of the ailments in the order of safety of available OTC drugs is as follows:'''
[[Image:effective ranking.jpg|center|thumb|800px]]
[[Media:Working of Effective Ranking & Scoring.xls| To see the calculation of the effective scores and effective ranking, click on this link]]

==Indian Market Survey - Physicians Preferences and Insights==
===Objectives of the Survey===

The reason for carrying out this research is to determine the scope of potential switch of prescription drugs to over the counter drugs in the Indian pharma industry. The study is particularly focused at the scope of making statins, a drug for reducing cholesterol level, available over-the-counter. The study aims to understand how successful a switch would be, and if it is safe for such drugs to be made available without prescription. The study also aims at determining the marketing pattern of over the counter drugs, and how it can be improved in future.

The objectives for the survey are :

* To understand the effectiveness of OTC drug marketing campaigns in India
* To understand the source of information for the OTC drugs among doctors
* To explore the potential of switch from Rx to OTC drugs
* To gauge the current prescription pattern of statins in India
* To identify if statins can be switched to OTC

===Research Methodology===
The research instrument used was a questionnaire survey administered to collect empirical data. The physician responses were kept confidential to encourage openness and disclosure. The respondents rated the questions on Yes or No, ticked the relevant choices from the options available and ranked the options on a numerical scale. All the responses were coded using a binary system logic and analysis was done to derive insights there after.

===Sample Size and Screening Criteria===
'''Screening Criteria'''
{|border="2" align = "center" cellspacing="0" cellpadding="4" width="60%"
|align = "center" bgcolor = "#8DB4E3" colspan = "2"|'''Screening Criteria'''
|-
|align = "center"|Medical Specialty
|align = "center"|General Physician, Consulting Physician, Gynaecologist, Dermatologist, Cardiologist, Pediatrician
|-
|align = "center"|No. of years in practice
|align = "center"|10
|-
|align = "center"|No. of patients consulting per month
|align = "center"|150
|-
|}

 

'''Sample Size'''
{|border="2" align = "center" cellspacing="0" cellpadding="4" width="25%" align = "center"
|align = "center" bgcolor = "#8DB4E3"|'''Gender'''
|align = "center" bgcolor = "#8DB4E3"|'''Sample Size'''
|-
|align = "center"|Male
|align = "center"|44
|-
|align = "center"|Female
|align = "center"|16
|-
|align = "center" bgcolor = "#C5D9F1"|'''Total Physicians'''
|align = "center" bgcolor = "#C5D9F1"|'''60'''
|-
|}
 

{|border="2" cellspacing="0" cellpadding="4" width="25%" align = "center"
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Medical Specialty-wise Breakup'''
|-
|General Physician
|align = "center"|17
|-
|Consulting Physician
|align = "center"|9
|-
|Gynecologist
|align = "center"|9
|-
|Dermatologist
|align = "center"|4
|-
|Cardiologist
|align = "center"|12
|-
|Pediatrician
|align = "center"|6
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Geographywise Breakup'''
|-
|Mumbai
|align = "center"|15
|-
|Hyderabad
|align = "center"|15
|-
|Delhi NCR
|align = "center"|14
|-
|Bangalore
|align = "center"|16
|-
|}
 

===Survey Results===
* 97% of the Indian doctors feel that the usage of OTC drugs has increased in the past 5 years
* Indian doctors feel that the usage of OTC drugs has increased by more than 50% in the past 5 years
* Ease in the availability of OTC drugs, Advertisements and Saving time are the major reasons for increase in the usage of OTC drugs
{|align = "center" width="100%"
|[[Image:Opinion on increased usage - India1.jpg|left|thumb|520px]][[Image:Reasons for increase in OTC Usage - India.jpg|right|thumb|520px]]
|-
|}
 
* Headache, Cold/Cough and acidity are the most common ailments for which physicians prefer giving an OTC drug
[[Image:Physician preferences for minor ailments - india.jpg|center|thumb|603px]]
 
* More than 80% of the patients are not prescribed OTC drugs beacuse of their prior medical history
[[Image:non pres due to medical history - india.jpg|center|thumb|619px]]
 
* Only 13% of the doctors feel that the information on the labels of OTC drugs is sufficient
* 98% of the doctors feel that drug-drug interactions might be a potential danger for OTC drugs
* 48% of the patients come once a month to doctor due to side effects caused by OTC drugs
[[Image:Patients coming due to side effects - India.jpg|center|thumb|554px]]
 
* 95% of the doctors feel that the problem of taking OTCs in India is serious
[[Image:Seriousness of taking otc - india.jpg|center|thumb|547px]]
 

'''The effective ranking of the ailments in the order of safety of available OTC drugs is as follows:'''
[[Image:effective ranking - india.jpg|center|thumb|800px]]
[[Media:Working of Effective Ranking & Scoring - India.xls| To see the calculation of the effective scores and effective ranking, click on this link]]
 

* 72% of the doctors see an opportunity for Rx-to-OTC switch in Indian pharma market
* Drugs relating to Vitamins, Antacids, Cuts, wounds and burns & Cold/Cough have a better potential to do well as an OTC drug
[[Image:category with better potential for switch - india.jpg|center|thumb|570px]]
 

'''Effectiveness of marketing campaigns'''
* Advertisements are a major source of information for Indians on OTC drugs
[[Image:Source of info - india.jpg|center|thumb|514px]]
 

* Only 23% of the doctors permit marketing executives to market OTC products through them
* Quality is the most important factor affecting the choice of a drug
[[Image:factor affecting choice of a drug - india.jpg|center|thumb|484px]]
 

'''Results on Statins'''
* More than 50% of the patients with high cholesteral level fall in the age group of 40-60 years
* 73% of the patients with high cholesteral level are prescribed Statin by doctors
{|align = "center" width = "90%"
|[[Image:age grp increased cholesterol - india1.jpg|left|thumb|485px]][[Image:drug prescribed for cholesterol - india1.jpg|right|thumb|485px]]
|-
|}
 
* Atrovastatin and Rosuvastatin are prescribed more than 90% of the times (whenever statins are prescribed) by doctors to patients with high cholesterol level
[[Image:prescribed statin - india.jpg|center|thumb|526px]]
 
* Sale and effectiveness of the drug, Manufacturer of the drug and Patient type are the major factors for choosing any type/brand of statin
[[Image:factors for choosing statin - india.jpg|center|thumb|565px]]
 
* Only 25% of the doctors feel that statins safe to be made available as OTC drugs for low- to-moderate risk group

File:C U 1.JPG

2011-09-13T14:32:05Z

Abhay.goel:

File:C S 3.JPG

2011-09-13T14:30:02Z

Abhay.goel:

File:C L.JPG

2011-09-13T14:28:10Z

Abhay.goel:

File:800px-C L.JPG

2011-09-13T14:26:34Z

Abhay.goel:

File:VP F 2.PNG

2011-09-13T14:19:13Z

Abhay.goel:

File:C O.JPG

2011-09-13T14:12:05Z

Abhay.goel:

File:D O 2.JPG

2011-09-13T14:07:01Z

Abhay.goel:

File:S 3.PNG

2011-09-13T13:42:08Z

Abhay.goel:

Partner in sales planning

2011-09-13T13:31:15Z

Abhay.goel:

==Company Overview - Dolcera==


Located in Silicon Valley and Hyderabad, India, Dolcera was founded in 2004 as a professional services organization with a strong technology bent. Our focus is on providing clients with the technical, intellectual property and business information they need to develop new products and ideas, and to understand the competitive landscape and market environment. A particular focus of the organization is to apply tools such as wikis, data visualization, and information analysis to the challenge of finding and using relevant information in the age of data overload.
 

Our clients include a number of the world's largest legal and technical firms.
 

Our Services include

* Patent Research and Analytics
* Business and Market Research
* Collaboration and Knowledge Management

 

==Product Description==
Good Sales Lead Data is a must for every business; random junk calls can eat up hours and hours of a sales executive’s time each month. Even if the data is available, it’s outdated. This affects the Sales Planning Process of a company.

 
Dolcera helps in planning sales activities in most efficient way by providing relevant Contact Data. Our data is available on the cloud, and can be accessed from anywhere in the world. The data can be segregated on various parameters like Title, Departments, Role, etc.

 
However, it doesn’t make much sense until one knows how the company is structured. To overcome this, we have company specific organizational charts which help in gathering insights on the company and target business verticals/divisions accordingly. Our data is manually curated, as compared to updating via scripts and other external software resources. Having understood the importance of each contact and the difference it can make to the fortunes of any organization, we provide you with the best resources for you to run your Business.

 
[[image:C_O.JPG|550×393px|center|Product Description]]
 

==Our Offerings==
Sales Leads are the main drivers for Business Growth in any organization. At Dolcera, we partner with our clients in planning their sales processes by providing Complete, Normalized, Filterable and Manually curated Company/Contact data to help their Businesses grow .

The following are the broad range of our Service Offerings:

 
[[image:D_O_2.JPG|575×510px|center|Dolcera's Offerings]]

 

== Comparative Analysis of our Product ==
How are we different from others

 
{|border="2" cellspacing="0" cellpadding="4" width="70%" align="center"
|bgcolor = "#4F81BD"|'''Data Sources / Characteristics'''
|align = "Center" bgcolor = "#4F81BD"|'''Cloud Based Services'''
|align = "Center" bgcolor = "#4F81BD"|'''Organization Structures'''
|align = "Center" bgcolor = "#4F81BD"|'''Data Filterability'''
|align = "Center" bgcolor = "#4F81BD"|'''Data Normalization'''
|align = "Center" bgcolor = "#4F81BD"|'''View all e-mail ID's'''
|align = "Center" bgcolor = "#4F81BD"|'''Customization'''
|align = "Center" bgcolor = "#4F81BD"|'''Manual Curation'''
|align = "Center" bgcolor = "#4F81BD"|'''Service Support'''
|-
|'''Dolcera'''
|align = "Center"|'''Yes'''
|align = "Center"|'''Yes'''
|align = "Center"|'''Yes'''
|align = "Center"|'''Yes'''
|align = "Center"|'''Yes'''
|align = "Center"|'''Yes'''
|align = "Center"|'''Yes'''
|align = "Center"|'''Yes'''
|-
|bgcolor = "#8DB4E3"|'''Jigsaw'''
|align = "Center" bgcolor = "#8DB4E3"|'''Yes'''
|align = "Center" bgcolor = "#8DB4E3"|'''No'''
|align = "Center" bgcolor = "#8DB4E3"|'''Yes'''
|align = "Center" bgcolor = "#8DB4E3"|'''Yes'''
|align = "Center" bgcolor = "#8DB4E3"|'''Yes'''
|align = "Center" bgcolor = "#8DB4E3"|'''No'''
|align = "Center" bgcolor = "#8DB4E3"|'''No'''
|align = "Center" bgcolor = "#8DB4E3"|'''Yes'''
|-
|'''Hoovers'''
|align = "Center"|'''Yes'''
|align = "Center"|'''No'''
|align = "Center"|'''Yes'''
|align = "Center"|'''No'''
|align = "Center"|'''Yes'''
|align = "Center"|'''No'''
|align = "Center"|'''No'''
|align = "Center"|'''Yes'''
|-
|bgcolor = "#8DB4E3"|'''Businesscard2'''
|align = "Center" bgcolor = "#8DB4E3"|'''No'''
|align = "Center" bgcolor = "#8DB4E3"|'''No'''
|align = "Center" bgcolor = "#8DB4E3"|'''No'''
|align = "Center" bgcolor = "#8DB4E3"|'''No'''
|align = "Center" bgcolor = "#8DB4E3"|'''No'''
|align = "Center" bgcolor = "#8DB4E3"|'''No'''
|align = "Center" bgcolor = "#8DB4E3"|'''No'''
|align = "Center" bgcolor = "#8DB4E3"|'''Yes'''
|-
|'''Net Prospex'''
|align = "Center"|'''Yes'''
|align = "Center"|'''No'''
|align = "Center"|'''Yes'''
|align = "Center"|'''No'''
|align = "Center"|'''Yes'''
|align = "Center"|'''No'''
|align = "Center"|'''No'''
|align = "Center"|'''Yes'''
|-
|bgcolor = "#8DB4E3"|'''LinkedIn'''
|align = "Center" bgcolor = "#8DB4E3"|'''Yes'''
|align = "Center" bgcolor = "#8DB4E3"|'''No'''
|align = "Center" bgcolor = "#8DB4E3"|'''Yes'''
|align = "Center" bgcolor = "#8DB4E3"|'''No'''
|align = "Center" bgcolor = "#8DB4E3"|'''No'''
|align = "Center" bgcolor = "#8DB4E3"|'''No'''
|align = "Center" bgcolor = "#8DB4E3"|'''No'''
|align = "Center" bgcolor = "#8DB4E3"|'''Yes'''
|-
|'''OneSource'''
|align = "Center"|'''No'''
|align = "Center"|'''No'''
|align = "center"|'''Yes'''
|align = "center"|'''No'''
|align = "center"|'''No'''
|align = "center"|'''Yes'''
|align = "center"|'''No'''
|align = "center"|'''Yes'''
|-
|}

 

[[image:S_3.PNG|center|1175×578 px]]

 

==Our Value Proposition==
At Dolcera, we believe that a client satisfaction cannot be achieved without constant input and feedback from them. Hence Dolcera's process of client engagements emphasizes recurring client interactions and feedback ultimately leading to Customer Delight. In 7 years of our existence we haven't lost a single Client yet.

 
[[Image:VP_F_2.PNG|center|1140×384px|Focus on Customer Delight / Value Proposition]]
 

== Our Clients==
We take pride in ourselves, having worked with some of the world's largest companies. We have more than 40 Fortune 500 clients spread across North America, Europe and Asia.
 
With our clientele growing at a sound pace, Dolcera aims at building long lasting relationships by providing world class service and solutions. Here is a snapshot of a list of clients we work with.

 
[[image:C_L.JPG|800×473px|centre|Clientele|Our Clients Across various Verticals]]

 

== Data Sources ==
Our Data Sources Include top Databases, Company Filings and Reports such as:

[[image:C_S_3.JPG||center]]

 


== Contact Us ==
Contact us at our USA and India offices.
 
[[image:C_U_1.JPG|500×500px|centre|Contact Us|Contact us at our USA and India Offices]]

Main Page

2011-09-13T13:24:13Z

Abhay.goel: /* Others and CPG */

__NOTOC__

[[#Intellectual Property (IP) Services|Intellectual Property(IP) Services]] 
[[#Business & Information Research Services|Business and Information Research Services]] 
[[#Dolcera Technology Platforms|Dolcera Technology Platform]]

== Intellectual Property (IP) Services ==
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"
|-
! style="background:lightgrey;width:50%" valign = "top" align = "left"|
===Life Sciences and Chemistry===
! style="background:lightgrey; width:50%" valign = "top" align = "left"|

===Technology===
|-
| valign = "top" |
 Landscape reports 
* [[Alopecia - Hair Loss]] | ([http://www.youtube.com/watch?v=jAIoyKuKQ6o Video])
* [[Inflammation and cardiovascular drugs]] | ([http://www.youtube.com/watch?v=FVUFcz2dpIM Video])
* [[RNAi Database sample wiki]] | ([http://www.youtube.com/watch?v=nsZLUSPn3cg Video])
* [[Choline Bitartarate]]
* [[Non-wovens]]
* [[Pressure sensitive adhesives]] | ([http://www.youtube.com/watch?v=plP3TzjYsiQ Video])
* [[Ureteral Stent]]
* [[Smart Drug Delivery Systems]] | ([http://www.youtube.com/watch?v=vARe9eBFsq4 Video])
* [[Silicone Hydrogel contact lens]]
* [[SC Johnson]]
* [[Pinene: An off flavor in mango juice]] | ([http://www.youtube.com/watch?v=P4fI1rjPjSg Video])
* [[Bio-PET]]
* [[Interferon For Treatment of Melanoma]]
* [[Antibody against TNF]]
* [[Pressure sensitive adhesives in packaging]]
| valign = "top" |

 Landscape reports 
* [[Hybrid Electric Vehicle Battery System]]
* [[Supply Chain RFID Applications]]
* [[Insurance sector]]
* [[CDMA Basics]]
* [[Quality of Service on CDMA platforms]]
* [[OLED - Organic Light Emitting Diode]]
* [[Carbon Nanotubes (CNT)]] | ([http://www.youtube.com/watch?v=HvZqBy8XvIE Video])
* [[Metallic and Ceramic construction materials]]
* [[Transactional memory]]
* [[Invalidation Search on a patent in the semiconductors space|Invalidation Search]]
* [[Golf Club Head Landscape]]
* [[Variable Valve Timing - Sample]]
* [[Wind Energy]]
|-
| valign = "top" |

STN Search Reports
* [[Markush Search Report]]

Dashboard
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard - live]
** ([[Alopecia Areata Dashboard Screenshots|Screenshots only]])
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]
* [[Legal Updates Demo|Legal updates dashboard]]
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=587 RNAi Dashboard]
| valign = "top" |

Dashboard
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=27 Automotive dashboard - live]
** [[Automotive Dashboard Screenshots|Screenshots only]]
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 WiMAX dashboard - live]
** [[WiMAX Dashboard Screenshots|Screenshots only]]
* [http://www.dolcera.com/ipmapdemo/rfid_model.swf RFID dashboard]

IP Valuation

*[[Holographic Image Display]]
|-
| valign = "top" |

Prior Art / Invalidation / FTO Search
* [http://dolcera.com/client/d8r3/hairloss_map.htm Alopecia/Hair loss IPMap]
* [[Markush Structure Search Sample]]
 Study: In re Bilski Impact
* [[In re Bilski Impact assessed from US PAIR Information]]
| valign = "top" |

Prior Art / Invalidation / FTO Search
* [[Prior Art Search Process]]
* [http://www.dolcera.com/ipmapdemo/satellite_antenna/ipmap.html Satellite Antenna IPMap]
* [http://www.dolcera.com/ipmapdemo/rfid/ipmap.html RFID IPMap]
* [http://www.dolcera.com/ipmapdemo/multimodal_apps/ipmap.html Multimodal Applications IPMap]
* [http://www.dolcera.com/ipmapdemo/Invalidation_US4825448.htm Invalidation Claim Chart Sample]
|-
|}

===Clinical Trial Database===
*[[Clinical Trial Database]]

== Business & Information Research Services ==
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"
|-
! style="background:lightgrey" valign=top width=50% align = "left"|
===Life Sciences and Chemistry===
! style="background:lightgrey" valign=top width=50% align = "left"|
===Technology===
|-
| valign=top |
* [[Diabetes products and services]]
* [[Drug Metabolism]]
* [[Toxicology]]
* [[Osteoporosis]]
* [[Oral Diabetes Drugs]]
* [[Ureteral Stent]]
* [[Premium Coffee Consumers Market Segmentation|Premium Coffee - Market Positioning]]
* [[Dolcera's Poster on Industrial Biotechnology|Industrial biotechnology]]
* [[OTC products for acne treatment]]
* [[Botox - from Medical Procedure to Household Word]]
* [[Digestive Remedies Market in India and China]]
* [[OTC vs. Prescription Drugs]]
* [[Rx to OTC Switch-Market Analysis]]
* [[Vaccines Market in Western Countries]], Company Profile:[http://dolcera.com/wiki/index.php?title=GlaxoSmithKline_profile GlaxoSmithKline]
* [[Ureteral Stent - Market Analysis]], Company Profile:[[Boston Scientific - Company Profile |Boston Scientific ]]
* [[Cardiac Pacemakers]]
| valign=top |
* [[4G wireless technology developments]]
* [[LTE]]
* [[Femtocells]]
* [[HDTV in the US]]
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics Innovation Explorer]
* [[Web video]]
* [[OLED Mobile Phones Market Research and Analysis Report]] | ([http://www.viddler.com/explore/dolcera/videos/6/ Video])
* [[Virtualization]]
* [[Cloud Computing]]
* [[Estimation of liquid carrying vehicles in USA]]
* [[A market study on Hybrid vehicles and the concept of V2G]]
* [[Patent Valuation]]

|-
! style="background:lightgrey" valign=top width=50% align = "left"|

===Finance===
! style="background:lightgrey" valign=top width=50% align = "left"|
===Others and CPG===
|-
| valign=top |
* [[Innovative personal finance products]]
* [[Life Insurance Industry in US]]
| valign=top |
*[[Deodorants Market Analysis: Acquisition of Sanex by Colgate]]
*[[Partner in sales planning]]
|}

== Dolcera Technology Platforms ==
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"
|-
| align = "top" |

==== Dashboard 1.1 ====
* [http://www.dolcera.com/auth/dashboarddemo/dashboard.php?workfilegroup_id=154 Demo Dashboard (Alopecia)]
** [[Access details]]
* [[Sample list of patent numbers]]
* [http://www.dolcera.com/auth/index.php Dashboard login page]

==== [[Workflow for creating a Dashboard]] ====

==== IP and Products dashboard ====
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard]
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]
* [[Legal Updates Demo|Legal updates dashboard]]
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 4G wireless product and patent dashboard]

==== Patent-pathway mapping ====
* [[Inflammation and cardiovascular drugs#Interactive signaling pathways and patents|Patent-pathway mapping]]
==== Sequence dashboard ====
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]

==== Design analysis ====
* [http://www.dolcera.com/website/demos/dental/main.html Dental Implant Design Analysis]

==== Innovation explorer ====
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics innovation explorer]
==== KPort ====
* [http://dolcera.com/website/demos/kport/main.html Collaboration Portal]

|-
|}

Dolcera Offerings summary 
* [[Dolcera Offerings|Dolcera offerings summary]]

[[Technology Support]] 

Like any of these sample reports?
 '''These are sample reports with brief analysis''' 
'''Dolcera can provide a comprehensive report customized to your needs'''
{|border="2" cellspacing="0" cellpadding="4" align="center" "
|style="background:lightgrey" align = "center" colspan = "3"|'''[mailto:info@dolcera.com Buy the customized report from Dolcera]'''
|-
| align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]
|align = "center"| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]
|align = "center"| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]
|-
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]
|align = "center"| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]
|align = "center"| [http://www.dolcera.com/website_prod/industries Industry Focus]
|-
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]
|align = "center"| [http://www.dolcera.com/website_prod/tools Dolcera Tools]
|-
|}
 

----
{| style="border:1px solid #AAA; background:#E9E9E9" align="center"
|-
! style="background:lightgrey" | Contact Dolcera
|-
! style="background:lightgrey" | Samir Raiyani
|-
| '''Email''': [mailto:info@dolcera.com info@dolcera.com]
|-
| '''Phone''': +1-650-269-7952, +91-40-2355-3493
|}